**Chapter 7-CUSHING’S SYNDROME**

**Dr Petra Sulentic,** Specialist in general medicine, KBC Sestre Milosrdnice, Zagreb,
Croatia

**Dr Damian G. Morris MBBS BSc PhD FRCP,** Consultant Endocrinologist, The Ipswich Hospital, Suffolk IP4 5PN, UK

**Professor Ashley Grossman BA BSc MD FRCP FMedSci,** Professor of Endocrinology, Nuffield Dept. of Medicine, OCDEM, Churchill Hospital, University of Oxford

Oxford OX3 7LJ, UK

Revised August 2014

**INTRODUCTION**

Cushing’s Syndrome results from chronic exposure to excessive circulating levels of glucocorticoids. It is now more than one hundred years since Harvey Cushing reported the classical clinical syndrome that bears his name. Even now its investigation and management can vex the most experienced endocrinologist. It may be difficult to miss the diagnosis in its most florid form, but, given the high prevalence of many of its non-specific symptoms such as obesity, muscle weakness and depression, clinicians are now required to consider the diagnosis in its earlier manifestations. The plethora of investigations often needed for the diagnosis and differential diagnosis has grown over the intervening century, and require careful interpretation. In its severe form and when untreated, the metabolic upset of Cushing's syndrome is associated with a high mortality. However, more subtle excesses of cortisol may also have significant effects on glycaemic control and blood pressure, and may therefore be an important cause of morbidity. Treatment is often complex and may require all the modalities of surgery, radiotherapy and medical management.

**PATHOPHYSIOLOGY, AETIOLOGY AND EPIDEMIOLOGY OF CUSHING SYNDROME**

In normal physiology the final product of the hypothalamo-pituitary-adrenal (HPA) axis is the glucocorticoid cortisol, secreted from the zona fasciculata of the adrenal gland under the stimulus of adrenocorticotropin (ACTH) from the pituitary gland. ACTH is secreted in response to corticotrophin releasing hormone (CRH) and vasopressin from the hypothalamus. Cortisol exerts negative feedback control on both CRH and vasopressin in the hypothalamus, and ACTH in the pituitary. In normal individuals, cortisol is secreted in a circadian rhythm; levels fall during the day from a peak at 07.00h-08.00h to a nadir at around midnight: they then begin to rise again at 02.00h.

It is the loss of this circadian rhythm, together with loss of the normal feedback mechanism of the hypothalamo-pituitary-adrenal (HPA) axis, which results in chronic exposure to excessive circulating cortisol levels and that gives rise to the clinical state of endogenous Cushing's syndrome (1). Any of the numerous synthetic steroids that have glucocorticoid activity, administered in excessive quantities can give rise to exogenous Cushing's syndrome. This is the commonest cause of Cushing's syndrome seen in general clinical practice, usually due to treatment for chronic conditions such as asthma or rheumatological disease.

The aetiology of Cushing's syndrome can broadly be divided into two categories; ACTH-dependent and ACTH-independent (Table 1).

ACTH-*dependent* forms are characterized by excessive ACTH production, which stimulates all three layers of adrenal cortex and results in bilateral adrenal cortical hyperplasia and hypertrophy of adrenal gland. This results in an increased weight of adrenals, which often show micronodular or sometimes macronodular changes. Circulating glucocorticoids are increased and often to a lesser extent are accompanied by a rise in serum androgens.

ACTH-*independent* forms constitute a heterogeneous group characterised by low levels of plasma ACTH, either because of adrenal glucocorticoid hypersecretion or secondary to the exogenous application of glucocorticoids. Except for adrenal adenomas, which usually secrete only glucocorticoids, among the other endogenous adrenal entities there is usually also a rise in androgens and sometimes steroid precursors. The microscopic and macroscopic appearance of non-affected adrenal tissue mainly depends on the aetiology of disorder.

***Table 1****.* ***Aetiology of Cushing's syndrome***

**ACTH-dependent**

Pituitary-dependent Cushing's syndrome (Cushing's disease)

Ectopic ACTH syndrome

Ectopic CRH syndrome (very rare)

Exogenous ACTH administration

**ACTH-independent**

Adrenal adenoma

Adrenal carcinoma

ACTH-independent bilateral macronodular adrenal hyperplasia (AIMAH) – now known as bilateral macronodular hyperplasia (BMAH)

AIMAH secondary to abnormal hormone receptor expression/function

Primary pigmented nodular adrenal disease (PPNAD), associated with Carney complex or sporadic

McCune-Albright syndrome

Exogenous glucocorticoid administration

**ACTH-dependent Cushing's syndrome.**

**Cushing's Disease**

Pituitary-dependent Cushing's syndrome, better known as Cushing's disease, is the most common cause of endogenous Cushing syndrome, accounting for 60-80% of all cases. Epidemiologic studies from Europe suggest an incidence of between 0.7 and 2.4 per million per year (2;3).

It presents much more commonly in women, and usually between 25 and 40 years of age.

It is almost always due to a corticotroph adenoma (4;5). Although apparent nodular corticotroph hyperplasia (in the absence of an CRH-producing tumour) has been described, it is rare in large surgical series (6;7), and its existence is still debated.The majority of tumours are intrasellar microadenomas (<1 cm in diameter), although macroadenomas account for approximately 5-10% of tumours, and extrasellar extension or invasion may occur. True pituitary corticotroph carcinomas with extra-pituitary metastases causing Cushing's syndrome have also rarely been described (8;9).

Despite much research, the molecular pathogenesis of corticotroph adenomas remains unknown, but the evidence supports the concept of primary pituitary rather than a hypothalamic disorder (10)

Up to 40 percent of patients of older patients with long-existing Cushing’s disease develop ACTH-dependent macronodular adrenocortical hyperplasia. The adrenals tend to be enlarged, with occasional prominent nodules, but invariably with internodular hyperplasia; the feature that distinguishes this entity from ACTH-independent ones. (11-14).

**Ectopic ACTH syndrome & ectopic CRH tumors**

Most other cases of endogenous ACTH-dependent Cushing’s syndrome, after excluding Cushing disease, are associated with non-pituitary tumors secreting ACTH, referred to as the ectopic ACTH syndrome. Ectopic sources of ACTH derive from a diverse group of tumour types, which can broadly be divided into the group of highly malignant carcinomas and the more indolent group of neuroendocrine tumours, although this may be thought of as a continuum rather than as a binary separation. The most frequent cause is probably small-cell lung carcinoma, where it is estimated up to 12% of cases will have Cushing's syndrome (15). However, this may not be evident from series at endocrine centres where often more occult tumours are investigated (Table 2), and carcinoid (neuroendocrine) tumours tend to predominate. The ectopic ACTH syndrome is more common in men, and usually presents after the age of 40 years.

The ACTH precursor molecule, pro-opiomelanocortin (POMC) is not only expressed in normal pituitary but also in several normal extra pituitary tissues, as well as in some tumors (lung, testis) (16). The mechanism by which these non-corticotroph tumours express the pro-opiomelanocortin (POMC) gene is not fully understood but may be related to hypomethylation of the POMC promoter (17;18). In general, such tumours tend to produce higher amounts of POMC compared to ACTH, in contrast to the situation in Cushing’s disease (16). As well as producing ACTH and POMC, these tumours may also produce other pre-ACTH precursor peptides, so -called "big" ACTH (19;20), which may potentially be helpful in the differential diagnosis of these tumours (21). However, assays for these are not routinely available in clinical practice.

Isolated ectopic CRH production is difficult to diagnose and exceedingly rare, with just over 20 cases described in the literature (22). In general, patients secreting CRH ectopically usually also secrete ACTH, rendering the distinction of little practical value.

Table 2. Aetiology of the ectopic ACTH syndrome in patients seen at St. Bartholomew's Hospital 1969-2001

Site of secretion Female Male

Bronchial carcinoid tumor 11 2

Small cell lung carcinoma 1 5

Medullary thyroid carcinoma 3

Pancreatic carcinoid tumor 1 2

Thymic carcinoid tumor 1

Disseminated carcinoid tumor 1

Mesothelioma 1

Pancreatic carcinoma 1

Colonic carcinoma 1

Phaechromocytoma 1

Gall bladder carcinoma 1

Total 16 16

**ACTH-independent Cushing Syndrome**

ACTH-independent causes of Cushing syndrome, apart from exogenous glucocorticoids, encompass a heterogeneous group of diseases. The most common pathology is an adrenal adenoma or carcinoma. The latter may lack some of the classic histological features of malignancy, but can usually be differentiated on the basis of weight (more than 100g), nuclear pleomorphism, necrosis, mitotic figures, and vascular or lymphatic invasion. These features are incorporated in the Weiss score for the distinction between adenomas and carcinomas.

Adrenal adenomas occur most often around 35 years of age and are significantly more common in women, with an incidence of approximately 0.6 per million per year (23). The incidence of adrenal cancer is approximately 0.2 per million per year (23). It is one and a half times more common in women, and has a bimodal age distribution, with peaks in childhood and adolescence, and late in life (1; 24).

ACTH-independent bilateral macronodular adrenal hyperplasia (AIMAH) is a rare form of Cushing’s syndrome with sometime huge nodular adrenal glands on imaging. Most cases are sporadic, but a few familial cases have been reported (25). AS ACTH has been found within these tumours, a better term is bilateral macronodular hyperplasia (BMAH). In most the aetiology is unknown, but in a few cases the nodules have been shown to express increased numbers of receptors normally found on the adrenal gland, or ectopic receptors that then can stimulate cortisol production. The best described example is food-dependent Cushing’s syndrome, in which ectopic gastric inhibitory peptide (GIP) receptors on the adrenal glands respond to GIP released after a meal causing hypercortisolaemia (26). In one patient, treatment with octreotide ameliorated the syndrome (27). Abnormal expression of vasopressin, β-adrenergic, luteinising hormone/human chorionic gonadotropin, serotonin, angiotensin, leptin, glucagon, IL-1, and TSH have also been described and functionally linked to cortisol production (28). BMAH tissue may express more than one of these aberrant receptors (29). More recently, around one-third of patients with BMAH have been found to show germline mutations of the tumour suppressor gene ARMC5, with the nodules demonstrating second independent hits in the same gene: familial forms of BMAH have been described.

Cushing’s syndrome due to bilateral nodular adrenal disease can also be a feature of McCune-Albright syndrome (30). The characteristic features are fibrous dysplasia of bone, café-au-lait skin pigmentation, and endocrine dysfunction; pituitary, thyroid, adrenal, or most commonly gonadal hyperfunction (precocious puberty). This condition is caused by an activating mutation at codon 201 of the α-subunit of the G protein stimulating cyclic adenosine monophosphate (cAMP) formation. This occurs in a mosaic pattern in early embryogenesis (31). However, if this affects some adrenal cells the constitutive activation of adenylate cyclase leads to nodule formation and glucocorticoid excess. The normal adrenal cortex, where the mutation is not present, becomes atrophic (32).

Primary pigmented nodular adrenal disease (PPNAD), otherwise known as micronodular adrenal disease, is another rare form of Cushing’s syndrome. It is characterised by small or normal-size adrenal glands with cortical micronodules (average 2–3 mm) that may be dark or black in colour. The internodular cortex is usually atrophic, unlike in ACTH-dependent macronodular hyperplasia (33). Cases of PPNAD have been reported without Cushing’s syndrome. Bilateral adrenalectomy is curative. Most cases of PPNAD occur as part of the Carney complex in association with a variety of other abnormalities, including myxomas of the heart, skin or breast; hyperpigmentation of the skin, and other endocrine disorders (sexual precocity; Sertoli cell, Leydig cell, or adrenal rest tumours; and acromegaly). Cushing’s syndrome occurs in approximately 30% of cases of Carney Complex. The tumour suppressor gene PRKAR1A (type 1A regulatory subunit of protein kinase A) has been shown to be mutated in approximately half of patients with Carney complex. In isolated PPNAD, mutations in PRKAR1A and also the phosphodiesterase 11A (PDE11A) gene have demonstrated (34).

A missense mutation of the ACTH receptor resulting in its constitutive activation and ACTH-independent Cushing’s syndrome has also been reported (35).

Other very rare causes of Cushing's syndrome have been reported: adrenal rest tissue in the liver, in the adrenal beds, or in association with the gonads may produce hypercortisolaemia, usually in the context of ACTH-dependent disease after adrenalectomy (36-39). Ectopic cortisol production by an ovarian carcinoma has been reported (40).

The basis for iatrogenic Cushing’s syndrome was discussed earlier. The development of the features of Cushing’s syndrome depends on the dose, duration, and potency of the corticosteroids used in clinical practice. ACTH is rarely prescribed nowadays, but it will also result in Cushingoid features if administered long-term. Some features, such as an increase in intraocular pressure, cataracts, benign intracranial hypertension, aseptic necrosis of the femoral head, osteoporosis, and pancreatitis, are reported as more common in iatrogenic than endogenous Cushing’s syndrome, whereas other features, notably hypertension, hirsutism, and oligomenorrhoea/amenorrhoea, are less prevalent. However, it is unclear as to whether these are true differences.

**Pseudo-Cushing's syndrome**

Pseudo-Cushing's states are conditions in which a patient presents with clinical features suggestive of true Cushing's syndrome and with some biochemical evidence of hypercortisolaemia. Both settle after resolution of the pre-disposing condition. The pathophysiology has not clearly been established. Depression and alcohol abuse are the two most common such states (1).

**CLINICAL MANIFESTATIONS OF CUSHING’S SYNDROME**

The clinical manifestations in Cushing syndrome result from a chronic exposure to excess glucocorticoids and show a wide spectrum of abnormalities, from mild, subclinical disease to florid manifestations.

The classical impression of the disease in its most obvious form, as the association of gross obesity of the trunk with wasting of the limbs, facial rounding and plethora, hirsutism with frontal balding, muscle weakness, spontaneous bruising, vertebral fractures, hypertension and diabetes mellitus, is less commonly seen nowadays. More frequently, the clinical diagnosis may be equivocal because many symptoms common in Cushing's syndrome, including lethargy, depression, obesity, hypertension, hirsuitism, and menstrual irregularity, are also very common in the general population. Therefore, it is useful to have an investigation strategy exploring the more *specific* features considering the diagnosis. It is very helpful to notice presence of several signs and symptoms, accompanied by a progressive course. Sequential photographs of the patient over many years can be extremely helpful in demonstrating progression to a Cushingoid state.

The clinical manifestations are usually determined by the duration and amplitude of glucocorticoid exposure, but in some aggressive courses of ectopic ACTH secretion, such as small cell carcinoma, symptoms of hypercortisolism are hard to detect because of the predominant malignant signs and symptoms such as weight loss and anorexia.

The type of steroid excess is determined by the underlying condition. Adrenal adenomas generally secrete glucocorticoids, but in case of an ACTH dependent disease or a carcinoma additional hyperandrogenism is common.

It is important to observe that combinations of Cushingoid features very much depend on the natural course of its underlying cause.

Patients with the ectopic ACTH syndrome usually present with severe and rapidly developing metabolic signs, most prominently anorexia, myopathy and glucose intolerance. Because of severe hypercortisolaemia and additional mineralocorticoid effect, hypokalaemic alkalosis is found with peripheral oedema on clinical examination. The combination of rapid clinical deterioration, common hyperpigmentation, hypokalaemic alkalosis and clinical signs of mineralocorticoid excess should be indicative for suspicion of a small cell lung carcinoma secreting ACTH. In contrast, patients with ACTH producing carcinoids, because of the long duration of hypercortisolaemia before clinical presentation, tend to develop all of the typical Cushingoid features, complicating its differentiation from Cushing’s disease.

Patients with adrenal carcinomas have a rapid onset of symptoms, may complain of an abdominal pain accompanied with palpable tumour masses. In addition to hypercortisolism, they often secrete mineralocorticoids and androgens, therefore distinguishing them from benign adenomas which usually secrete cortisol alone.

In 10 percent of patients with adrenal incidentalomas, “subclinical” Cushing’s can be found; this is characterised by mild hypercortisolism without other obvious clinical manifestations of Cushing’s syndrome. As a result, not only clinical picture is dependable on the underlying condition and type of steroids, but also highly influenced by the sex of the patient.

Unlike men, where the main source of androgens is the testes, in women a substantial proportion of circulating androgens are adrenal in origin, such that the signs and symptoms of adrenal hyperandrogenism are readily diagnosed by symptoms of hirsutism and acne, and signs of virilisation.

Obesity and weight gain are among the most common signs in Cushing syndrome. The distribution of fat can be useful, as typically in Cushing's syndrome there is increased visceral adiposity giving rise to truncal obesity, fat deposition in the cheeks and temporal fossae ("moon face"), dorsocervical area ("buffalo hump"), and supraclavicular fat pads (41,42). Rarely, fat deposition in the epidural space can be manifest as a neurological deficit (43), while retrorbital deposition is noticeable as exophthalmos (44). In children, more generalised weight gain associated with growth retardation should highlight the possibility of the diagnosis (45). Other signs that are more discriminatory are proximal myopathy, osteoporosis, thin skin and easy bruising (46, 47).

Myopathy of proximal muscle of the lower limb and shoulder results from catabolic glucocorticoid effect. When assessing for myopathy it is useful to ask questions about function typically affected by proximal muscle weakness such as climbing stairs or getting up from a chair. Formal testing can be of leg extension whilst sitting, or rising unaided from a squatting position. Muscle weakness can be exacerbated by hypokalaemia, as a result of concomitant mineralocorticoid activity; it is uncommon in pseudo- Cushing states. (1)

Osteoporosis occurs in approximately 50% of adult patients (48) and can be assessed by formal bone densitometry, or from a history of fractures, typically vertebral due to the preferential loss of trabecular bone induced by glucocorticoids. Glucocorticoids inhibit osteoblast function (49). Vertebral compression fractures leads to height loss. Rib fractures are often painless, with typical radiographic appearance of exuberant callus. Also, osteonecrosis (aseptic necrosis) of the femoral head has been described, usually in relation to iatrogenic Cushing sydrome of chronic high dose glucocorticoid therapy (50). After successful treatment of the cause, bone density improves to a large extent (51; 52).

There are many changes in the skin and subcutaneous tissue, which are rarely seen in general population, suggesting the possibility of Cushing’s syndrome. (1; 41). The result of hypercortisolaemia is thinning of the skin, which is best tested over the dorsum of the hand, visible as “cigarette paper” (Liddle’s sign), but it is helpful to consider the age and gender of the patient as natural atrophy increases with age and female gender. In addition, skin thickness may be preserved in women with hyperandrogenaemia related to Cushing's syndrome.

The classic plethora is not only a consequence of skin thinning but also of a loss of a facial subcutaneous fat. Because subcutaneous fat is also diminished, patients suffer easy bruising, which often can be misinterpreted as senile purpura or even a coagulation disorder. Purple coloured "violaceous" striae greater than 1 cm in diameter are almost pathognomonic of Cushing's syndrome. Typically seen on the abdomen, they can also occur in other areas, such as the thighs, breasts and arms. More narrow and coloured striae are more commonly present, and should be differentiated from the typical healed silvery striae seen most commonly post-partum.

Increased fine non-pigmented vellus hair on the upper cheeks or forehead may be seen in Cushing’s syndrome, as well as more typical terminal hair hirsuitism on the face and body, reflecting increased androgens. Cutaneous fungal infections as truncal tinea versicolor and onychomicosis are often found.

Skin hyperpigmentation is much more common in ectopic Cushing syndrome (most often from small cell lung carcinoma) than Cushing’s disease. It is also associated with the rapid onset of profound weakness, often with little or no weight gain, and an absence of a gross Cushingoid appearance. However, other forms of the ectopic ACTH syndrome, particularly associated with neuroendocrine tumours, may be clinically indistinguishable from patients with other forms of hypercortisolism (53).

Severe hirsutism and virilisation strongly suggest an adrenal carcinoma (54).

Hypercortisolism may suppress other pituitary hormones. In both men and women, hypogonadotrophic hypogonadism is common and correlates with the degree of hypercortisolaemia (55; 56). Glucocorticoids inhibit gonadotrophin –releasing hormone pulsatility and the release of luteinising (LH) and follicle-stimulating hormone (FSH). Women experience menstrual irregularity, while both sexes have decreased libido. Gonadal dysfunction is reversible after correction of the hypercortisolaemia (55; 56). In addition, the coexistence of polycystic ovarian syndrome in Cushing’s syndrome is more common (57). There is reduced GH secretion during sleep and blunted GH responses to dynamic stimulation tests (58). Thyrotropin-releasing hormone and thyroid-stimulating hormone release has been shown to be disturbed, and in particular the nocturnal surge of thyroid-stimulating hormone is lost (59). This may not have a significant effect on free thyroid hormone levels during active hypercortisolaemia, but there is a significantly increased prevalence of autoimmune thyroid disease in patients successfully treated for Cushing’s syndrome, and therefore it is important to follow them with serial thyroid function tests (60;61).

Hypokalaemic metabolic alkalosis is related to the degree of hypercortisolaemia and represents a mineralocorticoid action of cortisol at the renal tubule due to saturation of the enzyme 11β-hydroxysteroid dehydrogenase type 2, which inactivates cortisol to cortisone and allows selective binding of aldosterone to mineralocorticoid receptor (62). In terms of hypersaturation, cortisol can now access the mineralocorticoid receptor and act as a mineralocorticoid. It occurs when urine free cortisol excretion is greater than about 4100 nmol per day (63). Therefore, although a more common feature of ectopic ACTH secretion, it may also occur in approximately 10% of patients with Cushing’s disease.

Cushing’s syndrome is characterised by insulin resistance and hyperinsulinaemia. Glucose intolerance is evident in 20%-30%, and overt diabetes mellitus in 30%-40% of patients, (64; 65). Glucocorticoids stimulate glycogen deposition, promote gluconeogenesis, inhibit glucose uptake in peripheral tissues, activate lypolisis and have a permissive effect on contra-regulatory hormones, glucagon and catecholamines. It has been suggested that 2-3% of overweight, poorly-controlled patients with diabetes may have occult Cushing’s syndrome, if investigated (66; 67). However, in the absence of clinical suspicion the percentage is probably lower (68; 69), and therefore it is probably not justified to screen for Cushing in poorly controlled diabetic patients unless other suggestive features are present (70). Hyperglycaemia becomes easier to control after treatment (71).

There is an increase in total cholesterol and triglyceride levels, and a variable effect on high-density lipoprotein (HDL). These changes are multifactorial, including cortisol effects on increased hepatic synthesis of very low density lipoprotein (VLDL), lipolysis, and free fatty acid metabolism (72).

The major cause of mortality in Cushing’s disease are cardiovascular events, and patients exhibit direct markers of accelerated cardiovascular disease, including increased carotid artery intima-media thickness and atherosclerotic plaques (73) as well as hypertension, glucose intolerance, overt diabetes mellitus, dyslipidaemia and visceral obesity. Overall, hypertension is common in patients with Cushing syndrome, (74). Severe hypertension with additional hypokalaemia is more prevalent in ectopic Cushing syndrome, usually best controlled with spironolactone (75) Cardiovascular risk markers continue to be present long after cure of the hypercortisolaemia (76) and cardiovascular risk remains increased (77; 78). Sympathetic autonomic function is also abnormal in patients with Cushing's syndrome (79), and the ECG abnormalities of a prolonged QTc dispersion (QTcd) and left ventricular hypertrophy have been identified as characteristic features in patients with Cushing's disease (80)

Hypercortisolaemia increases clotting factors including factor VIII, fibrinogen, and von Willebrand factor, and reduces fibrinolytic activity. This along with other risk factors such as obesity, surgery and invasive investigative procedures, results in a significantly increased risk of thrombotic events in patients with Cushing's syndrome (81). Rates of tromboembolic events, either postoperatively or unrelated to surgery, are higher in patients with Cushing’s syndrome than the estimated incidence in an age and sex matched control population, especially in the latter group unrelated to surgery (82).

Ophthalmic complications include glaucoma and exopthalmus due to retroorbital fat deposition. (83; 84). Cataract is rare, mostly a complication of diabetes (85).

Psychiatric symptoms such as insomnia, depression, anxiety, easy irritability, paranoid episodes, suicide or panic attacks are present in more than half of patients having any cause of Cushing’s syndrome. (86-88). Cognitive defects as learning, cognition and impairment of short-term memory may be prominent. (89; 90). These changes are not always reversible with treatment.

In patients there is a greater frequency of infections because of inhibition of immune function by glucocorticoids by decreasing the number of CD4 cells, NK cells and inhibition in cytokine synthesis (91-93), with predominant effects on cell-mediated immunity (TH1 responses) . The most common are bacterial infections, and special attention should be pointed at a possibility of opportunistic pathogens, especially in cases of severe hypercortisolism. (94; 95)

Some cases of ACTH-dependent Cushing's syndrome occur in a periodic or cyclical form, with intermittent and variable cortisol secretion, the symptoms and signs waxing and waning according to the active periods of the disease. These patients can cause particular diagnostic difficulty, as it is imperative that the diagnostic tests are performed in the presence of hypercortisolaemia to allow accurate interpretation. Patients may 'cycle in' or 'cycle out' over periods of months or years; if at presentation they are eucortisolaemic, they will need regular re-evaluation usually with urinary free cortisol or late-night salivary cortisol to allow full investigation at the appropriate time. Cyclicity can occur with all causes of Cushing’s syndrome (96).

**BIOCHEMICAL CONFIRMATION OF CUSHING’S SYNDROME**

As stated above, there are many clinical features in various combinations in Cushing’s syndrome, but a small number of pathognomonic ones, such as myopathy, skin thinning and bruising, usually suggest the need for biochemical investigation. The basis for establishing the diagnosis of Cushing’s syndrome is biochemical confirmation of hypercortisolism, prior to any test of the differential diagnosis in terms of a specific cause.

As noted above, hypercortisolaemia together with the loss of the normal circadian rhythm of cortisol secretion, and disturbed feedback of the HPA axis, are the cardinal biochemical features of Cushing's syndrome. Almost all tests to confirm the diagnosis are based upon these principles. Furthermore, to screen for Cushing's syndrome, tests of high *sensitivity* should be used initially so as to avoid missing milder cases. Tests of high *specificity* can then be employed to exclude false positives.

It is important to realise that the validation of the published test criteria employed have been on specific assays, and thus test responses should ideally be validated on the local assay used before the results can be interpreted in particular patients. This is aided by supra-regional and nationwide inter-assay quality control assurance (1).

Cortisol is normally secreted in a circadian rhythm, with the highest levels early in the morning and reaching their nadir levels at about midnight (<50 nmol/L;1.8 g/dl). In patients with Cushing’s syndrome the circadian rhythm is lost. However, most of the patients still maintain their morning values within the normal range, but have raised nocturnal levels, rendering midnight levels most useful diagnostically. The measurement of free serum cortisol is very challenging, so either levels of salivary cortisol or total serum cortisol are being used. However, exogenous oestrogens and some medical conditions (see below) will increase cortisol-binding globulin and therefore total cortisol levels. Hence, in all investigations relying on a serum cortisol assay that measures total cortisol, hormone replacement therapy or the oral contraceptive pill should be stopped some time prior to investigation. We currently wait for a period of 4-6 weeks, although it is likely that a shorter time off treatment may still be effective.

**Late night salivary cortisol**

Salivary cortisolmeasurement accurately reflects the plasma free cortisol concentration, because cortisol-binding globulin (CBG) is absent from saliva. Loss of the circadian rhythm of cortisol secretion by measuring night-time salivary cortisol can be utilised as a sensitive screening test for Cushing’s syndrome. Due to the simple non-invasive collection procedure which can conveniently be performed at home, and the fact that salivary cortisol is stable for days at room temperature, it offers a number of attractive advantages over blood collection, particularly in children. Assays using a modification of the plasma cortisol radioimmunoassay, enzyme-linked immunosorbent assay, or liquid chromatography tandem mass spectrometry are now widely available.

Over the past decade there has been considerable increasing interest in this test, and it has been evaluated at a large number of centres worldwide. In a recent meta-analysis of these studies, in adult patients the sensitivity and specificity of this test appears to be relatively consistent at different centres, and overall is 92% and 96% respectively (97). However, it should be noted that the diagnostic value cut-off varies between studies because of different assays and the comparison groups studied. Normal values also differ between adults and paediatric populations, and may be affected by other comorbidities such as diabetes (98), and the method by which the saliva is collected (99). Not surprisingly, this test performs less well in patients with subclinical Cushing's syndrome (100). Salivary rather than serum cortisol has been evaluated as the endpoint for the low-dose dexamethasone suppression test (LDDST). This has the potential benefit in terms of convenience but requires further evaluation (101;102). Salivary cortisol has also been advocated as a sensitive tool to detect recurrence or treatment failure in patients post-pituitary surgery for Cushing's disease (103;104).

In summary, late-night salivary cortisol appears to be a useful and convenient screening test for Cushing's syndrome, particularly in the outpatient setting. However, local normal ranges need to be validated based on the assay used and population studied.

**Urinary free cortisol**

Measurement of urinary free cortisol (UFC) is a non-invasive test that is widely used in the screening of Cushing's syndrome. Under normal conditions, 10% of plasma cortisol is 'free' or unbound and physiologically active. Unbound cortisol is filtered by the kidney, with the majority being reabsorbed in the tubules, and the remainder excreted unchanged. As serum cortisol increases in Cushing’s syndrome, the binding capacity of CBG is exceeded and a disproportionate rise in UFC is measured. Thus, 24-hour UFC collection produces an integrated measure of serum cortisol, smoothing out the variations in cortisol during the day and night. In a series of 146 patients with Cushing's syndrome, UFC measurement was shown to have a sensitivity of 95% for the diagnosis (105). However, within this series 11% had at least one of four UFC collections within the normal range, which confirmed the need for multiple collections. Furthermore, this sensitivity figure is based on the more florid case, and is likely to be much less for the more common subtle cases now being seen.

The major drawback of the test is the potential for an inadequate 24-hour urine collection, and written instructions must be given to the patient. Also, multiple collections reduce the possibility of overlooking in episodic cortisol secretion, sometimes seen in adrenal adenomas. In addition, simultaneous creatinine excretion in the collection should be measured to assess completeness, and should equal approximately 1g/ 24 hours in a 70kg patient (variations depend on muscle mass). This should not vary by more than 10% between collections in the same individual (54). Cortisol to creatinine ratio in the first urine specimen can be used as a screening test, especially when cyclic secretion is suspected (106), with the cortisol to creatinine ratio over 25 nmol/mmol being suggestible for Cushing’s syndrome.

The 24 hour UFC is of little value in the differentiation from pseudo-Cushing's states (107;108), although obesity *per se* does not appear to confound the results (109).

High-performance liquid chromatography or tandem mass spectrometry are now used to measure UFC, which overcomes the previous problem with conventional radioimmunoassays of cross-reactivity of some exogenous glucocorticoids and other structurally similar steroids (110). Drugs such as carbamazepine, digoxin and fenofibrate may co-elute with cortisol during high-performance liquid chromatography and cause falsely elevated results (111;112).

In summary, UFC measurements have a high sensitivity if collected correctly, and several completely normal collections make the diagnosis of Cushing's syndrome very unlikely. Values greater than fourfold normal are rare except in Cushing's syndrome. For intermediate values the specificity is somewhat lower, and thus patients with marginally elevated levels require further investigation (1). It is our opinion that the test is of little use for screening, and in general we rarely utilise it nowadays.

**Low-dose dexamethasone suppression test (LDDST)**

This test works on the principle that in normal individuals administration of an exogenous glucocorticoid results in suppression of the HPA axis, whilst patients with Cushing's syndrome are resistant, at least partially, to negative feedback. Dexamethasone is a synthetic glucocorticoid that is 30 times more potent than cortisol, and with an extremely long duration of action. It does not cross-react with most cortisol assays. The original low-dose dexamethasone test (LDDST) described by Liddle in 1960 measured urinary 17-OHCS after 48 hours of dexamethasone 0.5mg 6 hourly (113). However, the simpler measurement of a single plasma or serum cortisol has been validated in various series and gives the test a sensitivity of between 95% and 100% (114-116).

The overnight LDDST was first proposed by Nugent *et al* in 1965; this measures a 09.00h plasma cortisol after a single dose of 1mg dexamethasone taken at midnight (117), and is thus considerably easier to perform. Since then, various doses have been suggested for the overnight test, between 0.5 and 2mg, and various diagnostic cut-offs have been used (118-120). There appears to be no advantage in discrimination between 1mg and 1.5mg or 2mg (121). Although higher doses have been tried, the increased suppression in some patients with Cushing's syndrome significantly decreases the sensitivity of the test (122).

In a comprehensive review of the LDDST, both the original 2-day test and the overnight protocol appear to have comparable sensitivities (98%-100%) using the criteria of a post-dexamethasone serum cortisol of <50nmol/l (1.8 g/dL) (123). However, the *specificity* is greater for the 2-day test (95%-100%) compared to the overnight test (88%) (123).

If the overnight test is used, we suggest that a dose of dexamethasone 1mg at midnight and a threshold of <50nmol/l (1.8 g/dL) at 09.00h will rarely lead to the diagnosis being missed, but false positives remain significant. In general, the overnight test is an excellent screening test, and we use the LDDST as confirmation.

It should be noted that patients with PPNAD may show a paradoxical rise in cortisol levels to dexamethasone (124).

**2nd line tests**

In some patients with equivocal results other tests may be needed. The most useful of these are a midnight serum cortisol, and the dexamethasone-CRH test. Less reliable tests such as the insulin tolerance test (125), the loperamide test (126) , and the desmopressin test (47) are not in widespread use.

**Midnight serum cortisol**

Before the introduction of salivary cortisol measurement a midnight serum cortisol was the only reliable method used to determine loss of the circadian rhythm of cortisol secretion. It is still useful as a second line test in cases of diagnostic difficulty, and we are content to use it as a major test to exclude Cushing’s syndrome in problematic cases.

However, it is a burdensome test that requires that the patient should have been an in-patient for at least 48 hours to allow acclimatisation to the hospital environment. The patient should not be forewarned of the test, and should be asleep prior to venepuncture, which must be performed within 5-10 minutes of waking the patient. A single sleeping midnight plasma cortisol <50nmol/l (1.8 g/dL) effectively excludes Cushing's syndrome (116), but false positive results do occur, particularly in the critically ill, in acute infection, heart failure, and in the pseudo-Cushing's state associated with depression (127).

An awake midnight cortisol of greater than 207 nmol/l (7 mg/dL) was reported to show 94% sensitivity and 100% specificity for the differentiation of Cushing's syndrome from pseudo-Cushing's states (128).

**The dexamethasone-CRH test**

In 1993 the combined dexamethasone-CRH (Dex-CRH) test was introduced for the difficult scenario of the differentiation of pseudo-Cushing’s states from true Cushing’s syndrome in patients with only mild hypercortisolaemia and equivocal physical findings (107). The theory being that a small number of patients with Cushing's disease as well as normal individuals will show suppression to dexamethasone, but those with Cushing's disease should still respond to CRH with a rise in ACTH and cortisol. In the original description of the test, dexamethasone 0.5 mg every 6 hours was given for eight doses, ending 2 hours before administration of ovine CRH (1 µg/kg intravenously) to 58 adults with UFC less than 1000 nmol/day (360 µg/day). Subsequent evaluation proved 39 to have Cushing’s syndrome and 19 to have a pseudo-Cushing’s state. The plasma cortisol value 15 minutes after CRH was less than 38 nmol/L (<1.4 µg/dL) in all patients with pseudo-Cushing’s states and greater in all patients with Cushing’s syndrome. A prospective follow-up study by the same group in 98 patients continued to show the test to have an impressive sensitivity and specificity of 99% and 96%, respectively (129). Importantly, in these two studies although eight of 59 patients with proven Cushing's disease showed suppression to dexamethasone, all were correctly characterised after CRH.However, the results from a number of other smaller studies have challenged the diagnostic utility of this test over the standard LDDST. Overall, in these reports the specificity of the LDDST in 92 patients without Cushing's syndrome was 79%, versus 70% for the Dex-CRH. The sensitivity in 59 patients with Cushing's syndrome was 96% for the LDDST versus 98% for the Dex-CRH (130). It is perhaps not surprising that the diagnostic utility of the Dex-CRH has altered with further studies at more centres. There are a number of reasons why there might be the case: variable dexamethasone metabolism in individuals; different definitions of patients with pseudo-Cushing's; different protocols and assays; and variable diagnostic thresholds. It is recommended that if this test is used, a dexamethasone level is measured at the time of CRH administration and the serum cortisol assay is accurate down to these low levels (70).

**The Differential Diagnosis of Cushing's syndrome**

Once Cushing's syndrome has been diagnosed, the next step is to differentiate between ACTH-dependent and ACTH-independent causes by measurement of plasma ACTH. Modern two-site immunoradiometric assays are more sensitive than the older radioimmunoassays and therefore provide the best discrimination. Rapid collection and processing of the sample is essential as ACTH is susceptible to degradation by peptidases so that the sample must be kept in an ice water bath and centrifuged, aliquoted, and frozen within a few hours to avoid a spuriously low result. Measurements are usually taken on two different days to avoid misinterpretation because of ACTH episodic secretion. The circadian rhythm of ACTH in patients having Cushing’s syndrome is lost, as it is for cortisol measurement, and the optimal sample should be taken at 08.00-09.00h. (131)

It is useful to duplicate this test because patients with ACTH-dependent Cushing’s disease have been shown to have on occasion ACTH levels less than 10 ng/L (2 pmol/L) on conventional radioimmunoassay (132). Consistent ACTH measurements of <10 ng/L (2pmol/L) essentially confirm ACTH-independent Cushing's syndrome and radiologic evaluation of adrenals is the next step in diagnosis. Conversely, if levels are consistently greater than 20-30 ng/L (4-6pmol/L), Cushing's syndrome is ACTH-dependent, due to pituitary disease or ectopic ACTH/CRH secretion.

Intermediate levels are less discriminatory, but a lack of ACTH response to the CRH test (see below) may be particularly helpful in these intermediate cases.

**Investigating ACTH-independent Cushing's syndrome**

Imaging of the adrenal glands is the mainstay in differentiating between the various types of ACTH-independent Cushing's syndrome. High-resolution computed tomography (CT) scanning of the adrenal glands is the investigation of choice and is accurate for masses greater than 1 cm and allows evaluation of the contralateral gland (133). In certain circumstances MRI may be useful for the differential diagnosis of adrenal masses; the T2-weighted signal is progressively less intense in phaeochromocytoma, carcinoma, adenoma, and finally normal tissue (134).

Adrenal tumours typically appear as a unilateral mass with an atrophic contralateral gland (135). If the lesion is greater than 5 cm in diameter it should be considered to be malignant until proven otherwise, and imaging characteristics should not be relied upon. In comparison to carcinomas, adrenal adenomas are usually smaller and have a lower unenhanced CT attenuation value. Signs of necrosis, haemorrhage and calcification are characteristics of carcinomas. (136). Additional laboratory diagnostics reveal solely raised cortisol levels in adenomas, unlike additionally raised androgen levels in carcinomas.

Bilateral adenomas can be present (135).

In PPNAD the adrenal glands appear normal or slightly lumpy from multiple small nodules, but are not generally enlarged (137).

Exogenous administration of glucocorticoids results in adrenal atrophy and very small glands may be a clue as to this entity.

BMAH is characterised by bilaterally huge (>5 cm) adrenals with a nodular pattern (12; 138).

Confusion can arise as the CT appearance of the adrenals in BMAH may be similar to the appearance seen in ACTH-dependent forms of Cushing's syndrome, where adrenal enlargement is present in 70% of cases (139), but the two can usually be distinguished by the ACTH level and the degree of adrenal enlargement. Some patients with Cushing's disease can also develop a degree of adrenal autonomy which can cause biochemical confusion (11).

**Identifying the source in ACTH-dependent Cushing's syndrome**

This has been one of the most significant challenges in the investigation of Cushing's syndrome in the past, although advances over the last 15 years have greatly improved our diagnostic capability. Cushing's disease accounts for by far the majority of cases of ACTH-dependent Cushing's syndrome, between 85% and 90% in most series. This depends on gender, and in our series of 115 patients with ACTH-dependent Cushing's syndrome, of the 85 women, 92% had Cushing's disease; this percentage was 77% in the 30 men (140). Therefore, even before one starts investigation, the pretest probability that the patient with ACTH-dependent Cushing’s syndrome has Cushing's disease is very high, and any investigation must improve on this pretest likelihood. However, as transsphenoidal pituitary surgery is widely accepted as the primary treatment of Cushing's disease, testing should be designed to avoid inappropriate pituitary surgery in patients with ectopic ACTH production. Thus, any test should ideally be set with 100% specificity for the diagnosis of Cushing's disease.

Levels of serum cortisol and ACTH tend to be higher in the ectopic ACTH syndrome, but there is considerable overlap of values, producing poor discrimination (Fig 1) (140;141). Hypokalaemia is more common than in patients with Cushing’s disease.

**Invasive testing**

**Bilateral inferior petrosal sinus sampling**

This is the "gold standard" test for distinguishing between Cushing's disease and an ectopic source of ACTH. The procedure involves placement of sampling catheters in the inferior petrosal sinuses that drain the pituitary. Blood for measurement of ACTH is obtained simultaneously from each sinus and a peripheral vein at two time points before and at 3-5 minutes and possibly also 10 minutes after the administration of ovine or human CRH (IV 1 μg/kg or 100μg respectively). A central (inferior petrosal) to peripheral plasma ACTH gradient of 2:1 or greater pre-CRH, or a gradient of 3:1 post-CRH, is consistent with Cushing's disease. The results from early series show these criteria to be 100% sensitive and specific for Cushing’s disease (142;143). However, it is now clear that false negative tests and to a smaller degree false positive test results do occur (144-146).

In order to minimise these it is important to ensure the patient is actively hypercortisolaemic (as above) at the time of the study (147), and that catheter position is confirmed as bilateral and any anomalous venous drainage noted by venography before sampling (148). For the diagnosis of Cushing's disease this test has a sensitivity of approximately 94% and specificity fractionally short of 100%. There appears to be no discriminatory difference between ovine or human sequence CRH. Recent data suggest that where is CRH is unavailable desmopressin 10 μg may be used instead (149).

It should be noted that the procedure is technically difficult, and should only be performed by radiologists experienced in the technique. The most common complications are transient ear discomfort or pain, and local groin haematomas. More serious transient and permanent neurological sequelae have been reported, including brainstem infarction, although these are rare (<1%), and most have related to a particular type of catheter used (150; 151); if there are any early warning signs of such events the procedure should be immediately halted. Patients should be given heparin during sampling to prevent thrombotic events (152). CRH itself is generally tolerated well, although patients may experience brief facial flushing and a metallic taste in the mouth. One case of CRH inducing pituitary apoplexy in a patient with Cushing’s disease has been reported (153). There appears to be no advantage in trying to sample the cavernous sinus. Sampling of the internal jugular veins is a simpler procedure but is not as sensitive as BIPSS (154).

BIPSS has also been suggested to help to lateralise microadenomas within the pituitary using the inferior petrosal sinus ACTH gradient (IPSG), with a basal or post-CRH inter-sinus ratio of at least 1.4 being the criteria for lateralisation used in all large studies (143;144;155;156). In these studies the diagnostic accuracy of localisation as assessed by operative outcome varied between 59% and 83%. This is improved if venous drainage is assessed to be symmetric (157). The accuracy of lateralisation appears to be higher in children (90%), a situation where imaging is often negative (158). There is some discrepancy between studies as to whether CRH improves the predictive value of the test (159). If a reversal of lateralisation is seen pre- and post-CRH, the test cannot be relied upon (160).

**Non-invasive tests**

**High dose dexamethasone suppression test**

As with the LDDST, the high dose dexamethasone suppression test (HDDST) was originally proposed by Liddle to differentiate between cortisol-secreting adrenal tumours and Cushing's disease (113). The HDDST’s role in the differential diagnosis of ACTH-dependent Cushing’s syndrome is based on the same premise: that most pituitary corticotroph tumors retain some albeit reduced responsiveness to negative glucocorticoid feedback, whereas ectopic ACTH-secreting tumours like adrenal tumours typically do not, with the exception of some neuroendocrine tumors, mainly bronchial (161;162).

The test is performed according to the same protocol as the LDDST either as 2mg 6 hourly for 2 days, or as an overnight using a single dose of 8mg of dexamethasone at 23.00h. The latter is more convenient for a patient because a single blood specimen is being tested on the next day at 08.00h. In most patients with pituitary-dependant Cushing’s syndrome serum cortisol level is less than 5 mcg/dl (140 nmol/L). In normal subjects the level is usually undetectable. (113;163)

Overall, only about 80% of patients with Cushing's disease will show positive response of the test, defined by suppression of cortisol to less than 50% of the basal value. There are high number of false positives tests (~10-30%) seen in ectopic Cushing’s syndrome (163-168). Shifting the criteria can only increase sensitivity with a loss of specificity, and vice-versa. Therefore, the test achieves worse discrimination than the pretest probability of Cushing's disease. In addition, a recent study has shown that suppression to HDDST can be inferred by a > 30% suppression of serum cortisol to the 2-day LDDST (169). Therefore, we no longer recommend the routine use of the HDDST except when bilateral inferior petrosal sinus sampling is not available, and then only as part of a combined testing strategy with the CRH test (see below).

**The CRH test**

The use of the CRH (corticotrophin-releasing hormone) test for the differential diagnosis of ACTH-dependent Cushing's syndrome is based on the premise that pituitary corticotroph adenomas retain responsivity to CRH, while ectopic ACTH tumours lack CRH receptors and therefore do not respond to the agent.

CRH either 1 µg/kg or 100 µg synthetic ovine (oCRH) or human sequence CRH (hCRH) is given as a bolus injection and the change in ACTH and cortisol measured.

Human-sequence CRH has qualitatively similar properties to oCRH, although it is shorter acting with a slightly smaller rise in plasma cortisol and ACTH in normal and obese patients, and in those with Cushing's disease (170); this may be related to the more rapid clearance of the human sequence by endogenous CRH-binding protein (171). The availability differs worldwide with oCRH predominant in North America but hCRH elsewhere.

Different centres have used differing protocols, including type of CRH and sampling time-points, and thus there is little consensus on a universal criterion for interpreting the test. In one of the largest published series of the use of oCRH, an increase in ACTH by at least 35% from a mean basal (-5 and -1 minutes) to a mean of 15 and 30 minutes after oCRH in 100 patients with Cushing's disease and 16 patients with the ectopic ACTH syndrome gave the test a sensitivity of 93% for diagnosing Cushing’s disease, and was 100% specific. The best cortisol criterion proved less discriminatory (172). Conversely, in the largest series of the use of hCRH in 101 patients with Cushing's disease and 14 with the ectopic ACTH syndrome, the best criterion to differentiate Cushing's disease from ectopic ACTH syndrome was a rise in cortisol of at least 14% from a mean basal (-15 and 0 minutes) to a mean of 15 and 30 minutes, giving a sensitivity of 85% with 100% specificity. The best ACTH response was a maximal rise of at least 105%, giving 70% sensitivity and 100% specificity (140). In a multicentre analysis from Italy, both hCRH and oCRH were used in 148 patients with Cushing's disease and 12 with the ectopic ACTH syndrome. A maximal 50% increase in ACTH and cortisol levels were considered as consistent with Cushing's disease, excluding all patients with the ectopic ACTH syndrome and thus giving 100% specificity. The sensitivity and specificity for the ACTH response were comparable for the two types of CRH (sensitivity: 85% vs 87% for oCRH and hCRH respectively). However, the sensitivity for the cortisol response was significantly greater with oCRH than with hCRH (sensitivity: 67% vs 50% for oCRH and hCRH respectively) (173). The authors do not report in this paper or an associated publication (24) whether time-point combinations other than the maximal were analysed for the rise in cortisol. Indeed, our data show that if the *maximal* rise in cortisol is used the sensitivity falls to 71% (140). These results again demonstrate that specific criteria need to be developed for each test, and cannot readily be extrapolated from other similar but non-identical agents.

In summary, the CRH test is a useful discriminator between causes of ACTH-dependent Cushing's syndrome, particularly in a combined testing strategy with the HDDST or LDDST when diagnostic accuracy is greater than that of either test alone, yielding 98% to 100% sensitivity, and an 88% to 100% specificity (165;169;174) Which cut-off to use should be evaluated at individual centres, and caution should be exercised as there will undoubtedly be patients with the ectopic ACTH syndrome who respond outside these cut-offs. However, it should be remembered that responses to both CRH and high-dose dexamethasone are more frequently discordant in Cushing's disease due to a macroadenoma (175). Nevertheless, where BIPSS is unavailable, a response to both CRH (a rise) and the LDDST (a fall) renders an ectopic source extremely unlikely

**Testing with other peptides**

Both vasopressin and desmopressin (a synthetic long-acting vasopressin analogue without the V1-mediated pressor effects) stimulate ACTH release in Cushing’s disease, probably through the corticotroph-specific V3 (or V1b) receptor. Hexarelin (a growth hormone secretagogue) stimulates ACTH release probably occurs through stimulation of vasopressin release in normal subjects (176), and by stimulation of aberrant growth hormone secretagogue receptors in corticotroph tumours (177). These peptides have been utilised in a similar manner to CRH to try and improve the differentiation of ACTH-dependent Cushing’s syndrome, but have unfortunately proved inferior (178-180). However, in centres with no availability of CRH the desmopressin test may be an alternative. A combined desmopressin and hCRH stimulation test initially looked promising (181), but a further study of this combined test showed significant overlap in the responses (182). The inferior discriminatory value of these stimulants is most likely due to the expression of both vasopressin and growth hormone secretagogue receptors by some ectopic ACTH-secreting tumours (152; 183).

**Imaging**

**Pituitary**

Imaging of the pituitary is an important part of the investigation of ACTH-dependent Cushing's syndrome to identify a possible pituitary lesion and to aid the surgeon during exploration. However, the results must be used in conjunction with the biochemical assessment as approximately 10% of normal subjects may have pituitary incidentalomas on MRI (184).

Modern MRI techniques using T1-weighted spin echo and/or spoiled gradient recalled acquisition (SPGR) techniques will identify an adenoma in up to 80% of patients with Cushing’s disease (24;185;186). They provide greater sensitivity than conventional MRI but with more false positive results (186;187). On MRI, 95% of microadenomas exhibit a hypointense signal with no post-gadolinium enhancement (Fig 2); however, as the remaining 5% have an isointense signal post-gadolinium, pre-gadolinium images are essential (188).

CT has a sensitivity of only approximately 40%-50% for identifying microadenomas, and is thus significantly inferior to MRI (sensitivity 50%-60%)(24;189;190), and it should therefore be reserved for patients in whom MRI is contraindicated or unavailable. Computerised tomography (CT) imaging typically shows a hypodense lesion that fails to enhance post-contrast.

Preoperative localisation to one side of the pituitary gland by MRI had been advocated as better than BIPSS with a positive predictive value of 93% (145;191). Other groups have found MRI less effective (144;192). In addition, as noted above, we have found MRI often to be unhelpful in the paediatric age group, and BIPSS to be of significant value in these patients (158).

***Figure 2. Magnetic resonance imaging (MRI), showing a right sided hypointense (post-gadolinium) corticotroph adenoma (arrow).***

## Fig2

**Ectopic tumours**

Visualising an ectopic ACTH source can be a challenge, but in general patients should begin with imaging of the chest and abdomen with CT and/or MRI, bearing in mind likely sites (Table 2). The most common site of the secretory lesion is the chest, and although small cell lung carcinomas are generally easily visualised, small bronchial carcinoid tumours that can be less than 1cm in diameter often prove more difficult. Fine-cut high-resolution CT scanning with both supine and prone images can help differentiate between tumours and vascular shadows (1). MRI can identify chest lesions that are not evident on CT scanning, and characteristically show a high signal on T2-weighted and short-inversion-time inversion-recovery images (STIR) (193).

The majority of ectopic ACTH secreting tumours are of neuroendocrine origin and therefore may express somatostatin receptor subtypes. Therefore the radiolabelled somatostatin analogue (111In-pentetreotide) scintigraphy may be useful to show either functionality of identified tumours, or to try and localise radiologically unidentified tumours (194). Undoubtedly this is a useful technique, but to date there are only sporadic reports that it identifies lesions not apparent using conventional imaging (195;196). However, a lesion of uncertain pathology is more likely to represent a neuroendocrine tumour, and hence an ectopic source of ACTH, if somatostatin scintigraphy is positive.

Unless the tumours are metabolically active, which is not usually the case, 18-flurodeoxyglucose positron-emission tomography (PET) does not generally offer any advantage over conventional CT or MRI (197;198). However, it is probable that 67Ga-octroeotide PET scanning is more sensitive than conventional octreotide scintigraphy.

Investigative strategy for the diagnosis and differential diagnosis of Cushing’s syndrome

There have been a number of international consensus statements published for the diagnosis and differential diagnosis of Cushing's syndrome, the latest on the diagnosis in 2008 (70;152). It is recommended that UFC (at least two measurements), the LDDST, or late night salivary cortisol (two measurements) are used as the first line screening test. One other of these tests should confirm abnormal results. In patients with discordant results second-line tests should be used as necessary for confirmation. Once the diagnosis of Cushing’s syndrome is unequivocal, ACTH levels, the CRH test (combined with the LDDST or HDDST), together with appropriate imaging, are the most useful non-invasive investigations to determine the aetiology. BIPSS is recommended in cases of ACTH-dependent Cushing’s syndrome where the clinical, biochemical, or radiological results are discordant or equivocal. However, in many centres where BIPSS is available and validated, the practice is to use this test in almost all cases of ACTH-dependent Cushing’s syndrome.

**Treatment of Cushing’s syndrome**

Treatment should be directed toward resolving the primary cause of Cushing’s syndrome presuming accurate differential diagnosis. Hypercortisolism, accompanied with fatal consequences if left untreated, should controlled by all means. Whenever possible, surgery, regardless of aetiology, presents a first-line treatment option aiming for a permanent cure and resolving the hypercortisolism together with its clinical consequences. However, the approach to the patient with Cushing’s syndrome is individual, so radiation therapy or even medical therapy as first line treatment can be appropriate depending on aetiology, clinical state and the personal choice of a patient.

Following treatment, all of the signs and symptoms of adrenal deficiency should be promptly corrected with steroid replacement therapy. Associated medical disorders of Cushing’s syndrome such as diabetes mellitus, osteoporosis and hypertension should be treated, aiming to avoid permanent dependence on therapy after resolving the primary cause of Cushing’s syndrome.

**Treatment of Cushing’s disease**

The first-line therapy almost always consists of transsphenoidal surgery. Patients with persistent Cushing’s postoperatively, can be re-operated upon with a lower success rate than primary surgery and with higher rates of other pituitary hormonal deficiencies. Prior to repeated surgery it is wise to repeat diagnostic testing, especially if corticotropinoma has not been found on pathologic examination, to exclude the possibility of a a missed ectopic ACTH ACTH syndrome (6). Besides re-operation, patients can be treated either by radiotherapy, medical therapy, or as a definitive solution, bilateral adrenalectomy.

**Transsphenoidal surgery**

According to the relevant 2008 consensus statement on the treatment of ACTH-dependent Cushing's syndrome (199), transsphenoidal surgery is widely regarded as the treatment of choice for Cushing’s disease (200). Besides the traditional microscopic approach there is an endoscopic approach which appears useful in patients with persistent or recurrent disease (201;202) and is accompanied with a shorter hospital stay (203). It is likely that the great majority of surgery will be endoscopic in the future.

The procedure is not without risks, and in the European Cushing’s disease survey group of 668 patients, the perioperative mortality was 1.9%, with other major complications occurring in 14.5% (204). The frequency of reported adverse events varies widely: diabetes insipidus (either temporary or permanent) (3%-46%); hypogonadism (14%-53%); hypothyroidism (14%-40%); cerebrospinal fluid rhinorrhoea (4.6%-27.9%); severe growth hormone deficiency (13%); bleeding (1.3%-5%); and meningitis (0-2.8%) (204-207).

Where an adenoma is apparent at transsphenoidal exploration, a selective microadenomectomy of tumour tissue is performed, and the surgeon may be guided by pre-operative imaging. However, where no tumour is obvious, and there is no condition of fertility, subtotal resection of 85-90% of the anterior pituitary gland is done, leaving a small part near the pituitary stalk. The latter involves a substantial and unpredictable risk of future panhypopituitarism.

The overall remission rate combined for microadenomas and macroadenomas in various large series is in the order of 70%-79%, although higher rates of approximately 90% can be achieved with microadenomas (6;14;204;205;208). Remission rates are estimated upon postoperative pathologic and biochemical results, although both can be equivocal. Half of tumours cannot be preoperatively visualised (209), and therefore parts of the tumour can be overlooked intra-operatively and left behind affecting surgery success rate (210). Adenomas can rise near or within pituitary stalk (211), rarely in ectopic locations (212-214) and may show signs of microscopic invasion (215).

Prognostic markers of long-term remission are patients aged over 25 years, a microadenoma detected by MRI, lack of invasion of the dura or cavernous sinus, histological confirmation of an ACTH-secreting tumour, low postoperative cortisol levels and long-lasting adrenal insufficiency (199).

Of the patients achieving remission, about 10% of these will have a recurrence by 10 years and 20% by 20 years (216), and this emphasises the need for long-term annual follow-up based on the same diagnostic criteria as with initial diagnostics; salivary midnight cortisol, 24-hour urinary cortisol, and an overnight 1 mg dexamethasone suppression test results. Special attention should be paid to patients with intermittent hypercortisolism (217). A lower recurrence rate closely correlates with lower postoperative cortisol measurements as well as with complete postoperative recovery of HPA axis and responsiveness to insulin -induced hypoglycaemia (218)

Transsphenoidal surgery is also a useful procedure in patients with Nelson’s syndrome to reduce tumour size, and ameliorate hyperpigmentation. (219).

Thromboprophylaxis with low molecular weight heparin should be considered perioperatively in all surgical procedures for Cushing's syndrome (81)

In cases where patients are treated with adrenal steroid inhibitors prior to surgery, glucocorticoid replacement therapy may be necessary preoperatively.

**Post-operative evaluation and management**

It is usual to give glucocorticoid cover for transsphenoidal surgery at initial daily doses of up to 400 mg hydrocortisone (4 mg dexamethasone), tapering off within 1 to 3 days. Morning (09.00h) serum cortisol measurements are then obtained for 3 consecutive days starting 24 hours after the last glucocorticoid administration, during which time the patient should be closely observed for development of signs of adrenal insufficiency (220). However, where there is close post-operative supervision, it may be possible to assess early cortisol results in the absence of corticosteroid cover.

In the immediate postoperative period, there is a wide range of possible biochemical results, but elevated cortisol in 24-hour urine unequivocally favours operation failure with persistent disease. Postoperative hypocortisolemia (<50 nmol/L [1.8 µg/dL] at 09.00h) is probably the best indicator of the likelihood of long-term remission (218;221;222). However, detectable cortisol levels of less than 140 nmol/L (<5µg/dl) are also compatible with sustained remission (223;224). In cases of a mild or cyclic Cushing disease the normal corticotrophs may not be suppressed and sustain a normal cortisol level with a normal diurnal rhythm.

Higher post-operative cortisol levels are more likely to be associated with failed surgery; however, cortisol levels may sometimes gradually decline over 1-2 months reflecting gradual infarction of remnant tumour or a gradual loss of autonomy of the adrenal (223;225). Regardless of the possibility of this late remission, the approach should be individualised and additional testing done prior to 3 months if there is reason to believe in residual disease. Persistent cortisol levels greater than 140 nmol/L (>5µg/dL) 3 months after surgery require further investigation.

Persistent hypercortisolaemia after transsphenoidal exploration should prompt reevaluation of the diagnosis of Cushing’s disease, especially if previous diagnostic test results were indeterminate or conflicting, or if no tumour was found on pathological examination

The treatment options for patients with persistent Cushing’s disease include: repeat surgery, radiation therapy, and bilateral adrenalectomy. If immediate surgical remission is not achieved at the first exploration, early repeat transsphenoidal surgery including the endoscopic technique may be worthwhile in a significant proportion of patients, at the expense of an increased likelihood of hypopituitarism (202;226;227). Repeat sellar exploration is less likely to be helpful in patients with empty sella syndrome or very little pituitary tissue on MRI scans. Patients with cavernous sinus or dural invasion identified at the initial procedure are not candidates for repeat surgery to treat hypercortisolism and should receive alternative therapy.

Patients who are hypocortisolaemic should be started on glucocorticoid replacement. Hydrocortisone 20 mg total daily dose in three divided doses is the preferred choice. The largest dose (10mg) should be taken before getting out of bed, and the last 5mg dose should be taken no later than 18.00h because later administration of glucocorticoids may result in disordered sleep. This low dose of hydrocortisone should be used to avoid long-term suppression of the HPA axis. All patients receiving chronic glucocorticoid replacement therapy should be instructed that they are “dependent” on taking glucocorticoids as prescribed, and that failure to take or absorb the medication will lead to adrenal crisis and possibly death. They should be prescribed a 100-mg hydrocortisone (or other high dose glucocorticoid) intramuscular injection pack for emergency use. They should also obtain a medical information bracelet or necklace that identifies this requirement (*Medic-Alert* Foundation or similar). Education should stress the need for compliance with the daily dose of glucocorticoid; the need to double the oral dose for nausea, diarrhoea, and fever; and the need for parenteral administration and medical evaluation during emesis, trauma, or severe medical stress.

The patient should be told to expect desquamation of the skin, and flu-like symptoms (malaise, joint aching, anorexia, and nausea) during the early postoperative months, and that these are signs that indicate remission. Symptoms can be especially prominent in patients with long-standing, severe Cushing’s. Some of these symptoms have been related to high levels of circulating interleukin-6 (228). Most patients tolerate these symptoms of glucocorticoid withdrawal much better if they are forewarned and alerted to their positive nature. The glucocorticoid dose should not be increased in the absence of intercurrent illness based on these symptoms alone, because it constitutes iatrogenic hypercortisolism, but signs of adrenal insufficiency, such as vomiting, electrolyte abnormalities, and postural hypotension should be excluded (229).

Recovery of the HPA axis can be monitored by measurement of 09.00h serum cortisol after omission of hydrocortisone replacement. Because recovery after transsphenoidal surgery rarely occurs before 3-6 months and is common at 1 year, initial testing at 6 to 9 months is reasonable (230). If the cortisol is undetectable on 2 consecutive days, then recovery of the axis has not occurred and glucocorticoid replacement can be restarted. If the cortisol is measurable, adequate reserve of the HPA axis can be assessed using the insulin tolerance test (231), with a peak cortisol value of greater than 500 nmol/L (>18 µg/dL), indicating adequate reserve on modern assays (232). Many centres use the cortisol response to 250 µg synthetic (1-24) ACTH as an alternative means of assessing HPA reserve (233;234), but there is some controversy as to its reliability in this situation (235;236). If it is used instead of the insulin tolerance test, a 30-minute cortisol of greater than 500 nmol/L is probably more reliable (232). Glucocorticoid replacement can be discontinued abruptly if the cortisol response is shown to be normal. Where recovery of the HPA axis is only partial on dynamic testing, but the 09.00h cortisol levels are above the lower limit of the normal range (200 nmol/L [7 µg/dL]), it is reasonable to taper and stop the hydrocortisone unless symptoms of adrenal insufficiency occur. Patients need to continue to be aware of the continuing need for additional glucocorticoids at times of stress or illness and should be given a supply of oral hydrocortisone and an intramuscular injection pack. For patients with detectable but low 09.00h cortisol levels, the hydrocortisone replacement dose should be adjusted down if weight loss has occurred, and a slightly lower dose may be given. Assessment of adequate replacement of hydrocortisone dosing by measuring serum cortisol at various points throughout the day, ensuring that levels are always sufficient (>50 nmol/L [>1.8 µg/dL]) before each dose is useful. This may mean that the peak levels after each dose appear to be unphysiological, but there is a trade-off between mirroring a normal physiologic rhythm as far as possible and the inconvenience of multiple dosing. In the future modified release hydrocortisone may provide more physiological replacement (237).

Two late conundrums may arise: the questions of recurrence and permanent lack of recovery of the axis. Patients who articulate that the Cushing’s syndrome has returned are often correct, even before physical and biochemical evidence are unequivocal. Investigation is warranted in a patient with these complaints or with recurrent physical signs characteristic of hypercortisolaemia. UFC can be measured initially on dexamethasone 0.5 mg/day, if not yet weaned from glucocorticoids. Measurement of late-night salivary cortisol having omitted the afternoon dose of hydrocortisone may also be useful. However, ideally assessment of a cortisol circadian rhythm can be done as an inpatient having stopped the hydrocortisone completely.

If recurrent Cushing’s disease is diagnosed, the therapeutic options are the same as for persistent disease. It should be remembered when investigating recurrence that long-standing ACTH stimulation by a pituitary adenoma causing macronodular adrenal hyperplasia may subsequently involve semi-autonomous cortisol production (238).

If the UFC result is subnormal or low, the patient should be questioned about the actual dose of glucocorticoid that has been taken. Often, patients take additional hydrocortisone, either because they discover that this decreases the symptoms of glucocorticoid withdrawal or because they have increased the dose “for stress,” often without following strict guidelines. These patients have a suppressed axis and very slow regression of Cushingoid features because of exogenous hypercortisolism. They require education and support along with reduction in the daily dose of hydrocortisone to recommended levels. The patient who has a subnormal cortisol response to ACTH 3 years after transsphenoidal surgery (in the absence of over-replacement) is likely to proceed to life-long ACTH deficiency, but this is also highly indicative of a lack of recurrence long-term..

Post-operatively, assessment for deficiencies of other pituitary hormones should also be sought, and the appropriate replacement regimen initiated as necessary.

Diuresis is common after transsphenoidal surgery and may result from intraoperative or glucocorticoid-induced fluid overload or may be due to diabetes insipidus. For these reasons, assessment of paired serum and urine osmolality and the serum sodium concentration is essential. It is advisable to withhold specific therapy unless the serum osmolality is greater than 295 mOsm/kg, the serum sodium is greater than 145 mmol/L, and the urine output is greater than 200 mL/hour with an inappropriately low urine osmolality. Desmopressin (DDAVP, Ferring) 1 µg given subcutaneously will provide adequate vasopressin replacement for 12 hours or more. Hyponatraemia may occur in as many as 20% of patients within 10 days of surgery. This may be due to injudicious fluid replacement or the syndrome of inappropriate antidiuretic hormone secretion (SIADH) as is frequently seen after extensive gland exploration, and fluid intake should be restricted (239). While transient central diabetes insipidus is common, in about 20% of operations (240), a small minority of patients proceed to permanent diabetes insipidus, requiring long-term treatment with a vasopressin analogue.

The state of permanent diabetes insipidus is usually accompanied with other anterior pituitary hormone deficiencies (241).

Many glucocorticoid-induced abnormalities, including hypokalaemia, hypertension, and glucose intolerance, may be normalised during the postoperative period so that preoperative treatments for these need to reassessed.

**Bilateral Adrenalectomy**

Bilateral adrenalectomy is also an important therapeutic option in patients with ACTH-dependent Cushing’s syndrome not cured by other techniques, particularly in young patients desiring fertility where there are concerns over radiotherapy-induced hypopituitarism. However, it has the disadvantages of life-long glucocorticoid and mineralocorticoid replacement therapy, and increased peri-operative morbidity and mortality. In addition, the development of Nelson’s syndrome in patients with ACTH-secreting pituitary adenomas occurs in between 8% and 38% of cases (242). The chance of developing Nelson’s syndrome appears to be greater if adrenalectomy is performed at a younger age, and if a pituitary adenoma is confirmed at previous pituitary surgery (216;242). Prophylactic pituitary radiotherapy probably reduces the risk of developing Nelson’s syndrome (243). However, it may be best to hold radiotherapy in reserve and undertake regular MRI scanning of the pituitary, especially when imaging has originally not shown any clear tumour (244). Others have advocated unilateral adrenalectomy plus pituitary irradiation as an alternative to bilateral adrenalectomy, as it gives similar remission rates to primary transsphenoidal surgery (245), but this should be reserved for selected cases.

**Pituitary radiotherapy**

For patients in whom fertility represents an important issue and with uncertain preoperative localisation, radiotherapy is used as primary treatment, while in patients showing no signs of remission after transsphenoidal resection of a tumor, pituitary irradiation is one of the next treatment options. It may also be considered as primary therapy for children under age 18y, because results are comparable to surgery (246-248). Pituitary irradiation may also decrease the occurrence of Nelson's syndrome (large, locally invasive corticotrophinomas with hyperpigmentation) after medical or surgical adrenalectomy, but this has not been tested in a prospective randomised trial (249,250).

Primary pituitary radiotherapy for the treatment of Cushing’s disease in adults has been shown to produce rather poor long-term remission rates of around 50% (216;251). In contrast, as a second-line therapy to failed pituitary surgery, better results are achieved with around 80% showing long-term remission as defined by the normalisation of the clinical state and biochemical parameters (252;253). In children, however, not only primary therapy shows better results with cure rate of 80%, but also they respond more rapidly, usually within three months (247), while remission in adults usually occurs by two years although it can take considerably longer. Medical therapy to control hypercortisolaemia is usually utilised in the interim, and patients should be reassessed at least yearly. (254). In order to evaluate results of pituitary irradiation, urinary free cortisol or several serum cortisol levels throughout the day are measured and medical therapy should be stopped for several consecutive days, followed upon patient education of early recognition signs and symptoms of adrenal insufficiency in outpatient conditions.

Conventional pituitary radiotherapy using linear accelerator is delivered at a total dose of 4500 to 5000 cGy in 25 fractional doses over 35 days using a 3-or 5-field (opposed lateral fields and vertex field) technique.

Side effects when given as primary therapy are rare, but there is significant risk of growth hormone deficiency occurring early, while other anterior pituitary deficiencies may develop over time.(77;252).

There is some evidence of an increased risk of cerebrovascular complications, which is of concern particularly in younger patients (255), but not all studies agree and further studies are required (256).

The risk of optic neuropathy is low and probably less than 1% as long as low-dose fractions are used. Although meningiomas and gliomas have been reported after pituitary radiotherapy, it is not clear whether the incidence is significantly greater than the background risk of developing such tumours (257;258).

Stereotactic radiotherapy using a gamma-knife or Cyber-knife (‘radiosurgery’) is used to optimise the tumour dose and minimise radiation to other areas by delivering a single high dose to a small tumour. This approach ensures that the daily dose to neural tissue does not exceed 180 cGy to avoid the complications of optic neuritis and cortical necrosis associated with larger total and fractional doses (259), not to mention convenience for the patient receiving therapy in one treatment. It has been less well investigated so far, but has a number of theoretical advantages, including a possible reduction in risk of cerebrovascular disease. It is hard to make a direct comparison in effectiveness between methods because of the difference in size of the treated tumours (260;261). Most patients still develop endocrine deficiency in upcoming years after the treatment (262;263). Because of the high dose of delivered radiation, it is not suitable for large lesions because of the large volume of exposed tissue or for lesions near to the radiosensitive tissues; optic chiasm or optic nerves, because of potential for blindness. Otherwise, if adenoma is not close to the optic pathway, it is considered to be superior to conventional fractionated therapy. Gamma knife radiosurgery is probably the most widely used of these techniques. As adjunctive therapy after failed transsphenoidal surgery it achieves biochemical remission in about 55%, although follow-up times have not been as long as for conventional radiotherapy (269). It can also be used as salvage therapy in difficult tumours (265). Radiosurgery of the pituitary gland using proton beams has similar efficacy as second-line therapy (266), and while possibly more precise is not widely available. Cyber-knife radiotherapy for Cushing’s disease is less well described, but there are reports of some success in small numbers of patients (267).As with other forms of radiotherapy, new hormone deficiencies are the major side-effect.

**Medical therapy in Cushing’s disease**

Although the primary therapy of hypercortisolism in Cushing’s disease is surgical, medical therapy can be required in cases when surgery is delayed, contraindicated, or unsuccessful. The most commonly used therapy is adrenal enzyme inhibitors, but there are other possibilities. (please see below “Medical therapy in Cushing’s syndrome).

**Treatment for the Ectopic ACTH syndrome**

If the ectopic ACTH-secreting tumour is benign and amenable to surgical excision, such as in a lobectomy for a bronchial carcinoid tumour, the chance of cure of Cushing’s syndrome is high.

Local radiotherapy following surgical resection of an ectopic ACTH-secreting source may also be beneficial, particularly in non-metastatic thoracic carcinoid tumours (268;269)

The course of the disease is mainly determined by the type of tumour, presence of metastases and degree of hypercortisolism. The lowest survival rate comes with small lung cancer, medullary thyroid cancer and gastrinomas (270;271).

In patients with metastases solely in the liver, cryoablation, resection or even liver transplantation can be curable. Prognosis is the best in patients younger than 50 years of age, with primary bowel or lung carcinoids (272;273).However, if significant metastatic disease is present, surgery is not curative, although it may still be of benefit in selected cases.

Regardless of the prognosis, control over hypercortisolism should be established medically either by inhibiting steroidogenesis, or performing mitotane induced medical adrenalectomy. If medical management fails, surgical bilateral adrenalectomy may be an option. Patients in whom control over hypercortisolism is established can develop thymic hyperplasia (274), which should be distinguished from tumour metastases or a primary thymic tumour. In cases where primary tumour origin remains unknown, adrenal inhibitors therapy is maintained as long as the patient goes to periodic re-examination for tumour localisation (270;271).

Ectopic CRH syndrome is rare and usually is associated with pulmonary carcinoid tumors, following the same therapeutic principles as ACTH secreting tumours (275)

**Treatment of ACTH-independent Cushing’s syndrome**

Adrenalectomy is the treatment of choice for all cases of ACTH-independent Cushing’s syndrome. This is either unilateral in the case of an adrenal adenoma or carcinoma, or bilateral in cases of bilateral hyperplasia, either micronodular or macronodular. The only exception can be the case of milder hypercortisolism in macronodular hyperplasia, when unilateral adrenalectomy may provide hormonal control (276; 277). Preoperatively, adrenal enzyme inhibitor therapy can be used such that the clinical state of the patient is improved thus reducing the risk of complications. In cases where macronodular hyperplasia comes as a consequence of aberrant hormonal receptor, eucortisolaemia can be achieved by using the appropriate receptor blockade (278; 279).

In adrenal adenomas, cure following surgery in skilled hands approaches 100% (280), and is associated with low morbidity and mortality (281).

Laparoscopic adrenalectomy, both unilateral and bilateral, has been shown in experienced hands to be a safe procedure and in many centres has become the approach of choice for non-malignant disease. Its complication rate is lower than with the open approach, and the in-patient stay is significantly reduced (282).

In adrenal cancer; more aggressive surgical approaches probably account for the increase in life span reported in this disease (283;284). This approach may require multiple operations to resect primary lesions, local recurrences, and hepatic, thoracic, and, occasionally, intracranial metastases, and is usually accompanied by adjuvant mitotane as discussed below.

Overall, there is no significant evidence that radiotherapy improves survival in adrenocortical carcinoma, although in the literature there are sporadic reports that it may be helpful adjuvant treatment to radical surgery in selected cases and may decrease local recurrence (285-287).

**Medical therapy of Cushing’s syndrome**

The role of medical treatment of Cushing’s syndrome is an important one. It is the routine practice of many groups to pre-treat Cushing's syndrome patients prior to surgical treatment to reverse the hypercortisolaemia and its metabolic sequelae, and to hopefully reduce the complications of the definitive procedure. Similarly, medical treatment is desirable in patients with Cushing's disease whilst awaiting for pituitary radiotherapy to take effect. In patients where surgery and/or radiotherapy have failed, medical management is often essential prior to (or long-term as an alternative to) bilateral adrenalectomy.

Sometimes, in the occult ectopic ACTH syndrome, it may not always be possible to identify the source of secretion, and therefore medical management is desirable pending re-investigation. Finally, medical therapy is helpful as a palliative modality in patients with metastatic disease causing Cushing's syndrome.

The most commonly used agents are adrenal enzyme inhibitors, but adrenolytic agents, pituitary-targeted therapies or glucocorticoid-receptor antagonists are also used. Drugs can be used in combinations in lower doses, aiming for side effect reduction with synergistic effects.

When determining the approach to treatment, the first step is to determine whether the final goal is reducing the level of serum cortisol within normal values or complete cortisol secretion blockade. The latter approach is convenient for patients with more variable secretion, while patients showing less variability can benefit more from lowering the values to the normal range and therefore avoiding the necessity of steroid replacement therapy, as well as a possibility of side effects connected to the higher dosages required with that strategy.

**Adrenal enzyme inhibitors**

These agentsare primarily used as inhibitors of steroid biosynthesis in the adrenal cortex, and thus can be utilised in all cases of hypercortisolaemia regardless of cause, but most commonly in ACTH-dependent forms, often with rapid improvement in the clinical features of Cushing's syndrome. The most commonly used agents are metyrapone, ketoconazole, and in certain circumstances etomidate. When used in combinations, they have a synergistic therapeutic effect, yet lowering the rate of side effects.

**Metyrapone**

Metyrapone acts primarily to inhibit the enzyme 11β-hydroxylase, thus blocking the production of cortisol from 11-deoxycortisol in the adrenal gland (288). As a consequence to blockade of cortisol synthesis, levels of adrenal androgens and deoxycorticosterone rise. The subsequent elevation of 11-deoxycortisol can be monitored in the serum of patients treated with metyrapone. It should be noted that there may be some cross-reactivity from 11-deoxycortisol with some cortisol radioimmunoassays: this may result in an unnecessary increase in the metyrapone dose and subsequent clinical hypoadrenalism (289). It is preferable to measure the serum cortisol via liquid chromatography-tandem mass spectrometry in patients treated with metyrapone (290). The fall in cortisol is rapid, with trough levels at 2 hours post-dose, and in our unit we sometimes administer a test dose of 750 mg with hourly cortisol estimation for 4 hours (291). Maintenance therapy is usually in the range 500-6000 mg/day in 3-4 divided doses daily.

Metyrapone has been used to good effect to reduce the hypercortisolaemia in patients with Cushing's syndrome from adrenal tumours, the ectopic ACTH syndrome, and Cushing's disease. In the former, patients can be very sensitive to low doses of this agent, whilst in Cushing’s disease higher doses are often required. In Cushing's disease this can be due to the compensatory rise in ACTH in patients not having received pituitary radiotherapy. There have not been serious maternal or perinatal complications connected with the use of metyrapone in pregnant women, but question of safety remains open (292;293)

The principal side effects with metyrapone are hirsutism and acne (as predicted by the rise in adrenal androgens), dizziness and gastrointestinal upset. Because of the androgen effect the drug is not considered appropriate for the first- line therapy of long-term treatment in women (294;295). However, it is hypoadrenalism that remains the most important potential problem, and careful monitoring of treatment and education of the patient is required. If there is uncertainty as to whether the measured cortisol is valid, and not over-estimated by cross-reactivity, it may be appropriate to consider a block-and-replace regimen.

Hypokalaemia, oedema and hypertension due to salt retention because of mineralocorticoid activity of raised levels of deoxycorticosterone are infrequent (291), but may require cessation of therapy (296).

**Ketoconazole**

Ketoconazole is an imidazole derivative originally developed as an oral anti-fungal agent. It is a potent inhibitor of sex steroids (androstendione and testosterone) production by its action on C17-20 lyase, and cortisol secretion by 11β-hydroxylase inhibition (297-299). It also inhibits 17-hydroxylase and 18-hydroxylase activity, amongst other enzymes (300). It has also been reported to have a direct effect on ectopic ACTH secretion from a thymic carcinoid tumour (301), and possibly corticotroph ACTH release.

The treatment for Cushing's syndrome is usually started at a dose of 200 mg twice daily, with an onset of action that is slower than metyrapone. The usual maximum dose is 400mgs.

It has been used successfully to lower cortisol levels in patients with Cushing's syndrome of various aetiologies including adrenal carcinoma, the ectopic ACTH syndrome, and invasive ACTH-producing pituitary carcinoma, with doses required between 200-1200mg/day in up to 4 divided daily doses (302-304), although 2-3 times daily is more usual. Although there has not been consequences on human fetuses, considering animal teratogenity and toxicity the drug is not recommend for use during pregnancy (305; 306).

The principal side effect of ketoconazole is hepatotoxicity (307;308). A reversible elevation of hepatic serum transaminases occurs in approximately 5%-10% of patients, with the incidence of serious hepatic injury at around 1 in 15,000 patients (309). The hepatotoxicity appears to be idiosyncratic, but has been reported within 7 days of the initiation of treatment in a patient with Cushing's syndrome (310). Prior to the start of therapy liver function tests should be performed. The alanine aminotransferase (ALT) level should be monitored weekly within first month of therapy, then once a month in the following trimester and afterwards sporadically. If levels reach 3-times above the upper normal range, therapy should be discontinued. Other adverse reactions of ketoconazole include skin rashes and gastrointestinal upset (311), and one must always be wary of causing adrenal insufficiency (310;312).

Due to its C17-20 lyase inhibition and consequent anti-androgenic properties, ketoconazole is particularly useful in female patients where hirsutism is an issue, which may be worsened with metyrapone. Conversely, gynaecomastia and reduced libido in male patients may be unacceptable as a first-line long-term treatment and require alternative agents. However, replacement therapy is an option. On the other hand, women having lower levels of estradiol and testosterone do not experience clinically manifest disorder because of already usually present menstrual irregularity. It requires gastric acid for absorption, so should never be given with proton-pump inhibitors. One further advantage of ketoconazole is its inhibition of cholesterol synthesis, particularly LDL cholesterol (313), and in 34 patients with Cushing's syndrome the mean total cholesterol was reduced from 6.1 to 5.0 mmol/l on ketoconazole (311).

The triazole antifungal fluconazole can also be effective, but experience is limited. (314)

**Etomidate**

Etomidate is an imidazole-derived anaesthetic agent which was reported to have an adverse effect on adrenocortical function in 1983 (315). Compared to the other imidazole derivative ketoconazole, etomidate more potently inhibits adrenocortical 11β-hydroxylase, has a similar inhibition of 17-hydroxylase, but has less of an effect on C17-20 lyase (316). At higher concentrations it also appears to have an effect on cholesterol side-chain cleavage (317;318).

Following their initial report in 1983 (319), Allolio *et al* have shown that low-dose intravenous non-hypnotic etomidate (2.5mg/hour) normalised cortisol levels in 5 patients with Cushing's syndrome of various aetiologies (320). Since then, there have been a number of case reports on the use of etomidate in successfully reducing hypercortisolaemia in seriously-ill patients with either Cushing's disease or the ectopic ACTH syndrome (321-325).

It is usually given at a dose of 2.5 - 3.0mg/hour, which is adjusted based on the serum cortisol levels. It usually takes about 10 hours for cortisol to be lowered to within normal range (326). Etomidate is an effective agent that acts rapidly, but is limited in its use by the fact it has to be given parenterally.

However, in this situation it may be life saving. The preparation available in the USA contains the vehicle propylene glycol with the potential for nephrotoxicity, as opposed to the preparation available in Europe, which contains alcohol.

**Adrenolytic therapy**

Mitotane (o’p'DDD), an isomer of the insecticide DDD (belonging to the same family of chemicals as the insecticide DDT), was developed following the observation of adrenal atrophy in dogs administered DDD. Mitotane inhibits steroidogenesis by reducing cortisol and aldosterone production by blocking cholesterol side-chain cleavage and 11β-hydroxylase in the adrenal gland (327). It also acts as an adrenolytic drug, causing medical adrenalectomy, after being metabolised into an acyl chloride that binds in mitochondria and causes necrosis of adrenocortical cells (328,329)

Mitotane is used as a treatment for adrenal carcinoma and causes tumour regression and improved survival in some patients (330,331), and has a beneficial effect on endocrine hypersecretion in approximately 75% of patients (332). It is also utilised in Cushing's syndrome of non-malignant origin, and in this regard lower doses can be utilised (up to 4 g/day), thus reducing the incidence of side effects, particularly gastrointestinal (289;333). At these lower doses the onset of the cortisol lowering effect takes longer (6-8 weeks) than with higher doses. Mitotane should not be used in pregnant women, and reproductively active women use reliable contraception while on therapy. (334)

One problem even with lose-dose mitotane is the hypercholesterolemia (principally an increase in LDL-cholesterol), which appears to be due to the impairment of hepatic production of oxysterolds, normally a brake on the enzyme HMG Co A reductase (335). However, simvastatin, an HMG Co A reductase inhibitor, can reverse the hypercholesterolemia, and it or a similar agent should be used if necessary in patients treated with mitotane (335). Other side effects of mitotane include neurological disturbance; elevation of hepatic enzymes; hypouricaemia; gynaecomastia in men; and a prolonged bleeding time (332;336). Most importantly, it elevates cortisol-binding globulin, such that levels of total serum cortisol are misleading. Control should be titrated on urinary free cortisol or salivary cortisol.

In the long-term, measurement of blood levels can allow dose titration and reduction as appropriate. A therapeutic level of 14-20 mg/L has been recommended. Mitotane is taken up by fatty tissues; sometimes being released gradually several months after discontinuing therapy, therefore requiring adjustments in glucocorticoid therapy dosage (337).

Mitotane shows cytotoxic activity on both normal and tumorous tissue causing primary adrenal insufficiency and therefore requiring glucocorticoid replacement therapy. It tends to spare zona glomerulosa, but in a long-term use, mineralocorticoid replacement is also needed. (338)

In general, despite effective in other forms of Cushing syndrome, its use has been limited outside of adrenal carcinoma, in which cases it has recently been shown to prolong life (331).

**Other medical agents**

Somatostatin receptors have been demonstrated on both corticotroph adenomas, and some ectopic ACTH-secreting tumours. However, although octreotide has been helpful in reducing ACTH and cortisol levels in selected case reports of ectopic ACTH-secreting tumours there has been much more limited success in patients with Cushing's syndrome probably through down-regulation of receptor sub-type 2 in these tumours by hypercortisolaemia (339).

Recently, there has been renewed interest with the introduction of pasireotide (SOM230), a somatostatin analogue with a broader spectrum of activity for somatostatin receptor sub-types, including type 5, which is not downregulated during hypercortisolaemia. Ever since this agent was shown in vitro to reduce human corticotroph proliferation and ACTH secretion (340;341), there have now been a number of clinical trials published. In an initial phase II trial, pasireotide 600µg injected twice daily for 15 days reduced UFC levels in 76% of 29 patients and normalised levels in 17% (342). A multicentre phase III dose-randomised trial in 162 patients with either new, persistent, or recurrent Cushing's disease has presented 12 month results. At six months there was a reduction in UFC levels in 91 of 103 evaluable patients, with a median UFC reduction of 48%. Normalisation of UFC levels was achieved in 14.6% of patients on the 600µg dose twice daily, and 26% of patients on the 900µg twice-daily dose. Patients who showed <50% reduction in UFC levels from baseline by month two were unlikely to show improvement by month 6 or 12. The most clinically relevant adverse events were hyperglycaemia (39%), with 18% developing frank diabetes mellitus related to decreases in both insulin and incretin secretion, and and hypocortisolaemia (8%) (343;344).

Pasireotide should be given in a doze 600µg subcutaneously twice daily, with a possibility of increasing the dosage to 900µg twice daily after couple of months of therapy. In cases where there is no clinical response, it should be discontinued.

Pasireotide at a lower dose of 250µg three times daily has also been used in stepwise combination therapy with the dopamine agonist cabergoline (previously been demonstrated to have modest but variable efficacy as monotherapy in Cushing's disease (345;346), and ketoconazole. Pasireotide monotherapy induced normalisation of UFC levels in 5 of 17 patients (29%). The addition of cabergoline normalised UFC levels in an additional 4 patients (24%). The further addition of ketoconazole in the remaining 8 patients induced normalisation of UFC levels in 6 of these. Thus in total, remission was achieved in 88% of patients using combination therapy out to 80 days treatment (347). Therefore pasireotide represents a potential new treatment for Cushing's disease, although the frequency of hyperglycaemia is of major concern.

Temozolomide is an oral alkylating prodrug that is converted *in vivo* to the DNA repair inhibitor dacarbazine. Traditionally, this chemotherapy agent has been used in the treatment of malignant gliomas, but recent evidence suggests it is also useful in selected aggressive pituitary tumours including corticotroph pituitary carcinomas (348;349). Although, some reports suggested that the response to temozolomide in pituitary tumours can be predicted by low expression of the DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT), possibly related to MGMT gene promotor methylation (350;351), not all studies have confirmed this (352;353). However, the therapeutic response can usually be determined after 3 cycles of chemotherapy.

Retinoic acid has been found to inhibit ACTH-secretion and cell proliferation both *in vitro* in ACTH-producing tumour cell lines, and cultured human corticotroph adenomas, and *in vivo* in nude mice (354). However, clinical trials in man are limited.

The thiazolidinedione rosiglitazone, a PPAR-γ agonist, has been shown in supra-pharmacological doses to suppress ACTH secretion in human and murine corticotroph tumour cells. In addition, the development of murine corticotroph tumours, generated by subcutaneous injection of ACTH-secreting AtT20 cells, were prevented (355). It appears this is not specific to corticotroph adenomas, but also applies to other forms of pituitary tumour (356). However, the results in human subjects with Cushing's disease have been disappointing (357-360). This may be because doses used in the animal studies were much higher than the equivalent licensed dose in humans. Its use cannot be recommended, and indeed for other reasons it has now been withdrawn from the market.

In the rare causes of Cushing’s syndrome due to bilateral macronodular adrenal hyperplasia (BMAH) and aberrant receptor expression of GIP, β-adrenergic and LH/hCG receptors, specific receptor antagonists may prove to be useful (361). Although octreotide has been shown to have cause a therapeutic response in GIP-related AIMAH as mentioned above (27), others have found neither this somatostatin analogue or pasireotide to be helpful in inducing a sustained response (362).

Mifepristone (RU 486) as a potent antagonist of glucocorticoid and progesterone receptors, blocks the peripheral actions of glucocorticoids and progestogens (363; 364). As a consequence it also blocks glucocorticoid-induced negative feedback at the hypothalamo-pituitary level, inducing a rise in ACTH, arginine-vasopressin (AVP) and hence cortisol (365). It has, occasionally been given to patients with all forms of Cushing's syndrome, (366;367), showing effectiveness in rapid reducing symptoms of cortisol-induced psychosis (368;369), and the metabolic benefit of glycemic control and hypertension have been established (367). Although, it has proven to be effective in the treatment of hypercortisolaemia symptoms and signs (370;371), the major drawback is the lack of biochemical markers to asses either therapeutical effectiveness or possible hypoadrenalism. Adrenal insufficiency is challenging to treat, because the drug, besides blocking endogenous cortisol, also blocks the action of synthetic steroids as replacement therapy. Hypokalaemia is a frequent problem, although it responds well to spironolactone.

**Monitoring Treatment**

It is important to monitor all patients on medical therapy for Cushing’s syndrome, to assess the effectiveness of treatment, and in particular to avoid adrenal insufficiency. Serum cortisol level and/or urine cortisol level are used in order to estimate steroid inhibitor therapy. We use the mean of 5 serum cortisol measurements across the day, although others favour measurement of urinary free cortisol (UFC). A mean serum cortisol between 150 and 300 nmol/l (5.5-11 ug/dl) corresponds to a normal cortisol production rate (372), and this range should be the aim of therapy. As mentioned above, a liquid chromatography tandem mass spectrography cortisol assay is preferable in patients on metyrapone.

When mitotane is used, only measurement of 24-hour urinary free cortisol reflects therapy effectiveness and concentration of serum free cortisol, because mitotane reduces 17-OHCS excretion, which therefore cannot stand for correct measurements. Because it raises the level of cortisol binding globulin, level of total serum cortisol is inappropriate for monitoring of cortisol secretion, as it can be two to threefold elevated. (373; 374). Alternated levels of globulins explain why replacement dosage of steroids needs to be increased in case of an adrenal insufficiency.

**Cushing's syndrome in specific groups**

**Chronic Renal Failure**

Cushing’s syndrome in the setting of chronic renal failure is poorly described but may pose diagnostic difficulties. In chronic renal failure plasma levels of cortisol are generally normal but with some radioimmunoassays may be increased (375;376). ACTH levels are increased (377). Glomerular filtration rates of less than 30 mL/min result in decreased cortisol excretion and spuriously low UFC values (378). The ACTH and cortisol responses to ovine CRH may be suppressed in patient with renal failure except for those undergoing continuous ambulatory peritoneal dialysis (379). The metabolism of dexamethasone is normal in chronic renal failure, but the oral absorption can be altered in some patients. There is reduced degree of suppression of cortisol by dexamethasone suggesting a prolonged half-life of cortisol. Normal suppression to the overnight 1-mg LDDST is uncommon, and the 2-day LDDST does better in this regard (375;380).

**Paediatric Cushing’s syndrome**

The most common presentation of Cushing’s syndrome in children is growth retardation, whilst weight increases (45). However, one proviso is that patients with virilising adrenal tumours may show growth acceleration (381). Other virilizing signs such as acne and hirsutism are seen in approximately 50% of patients regardless of aetiology (45). Hypertension and striae are seen in approximately 50% of cases (382). Muscle weakness may be less common in the paediatric patient due to increased exercise (383). Psychiatric and cognitive changes may affect school performance; however, children may show “compulsive diligence” and actually do quite well academically (384). Headaches and fatigue are common (45). Cushing’s disease accounts for the between 75% and 80% of Cushing’s syndrome in older children, but before the age of 10 years ACTH-independent causes of Cushing’s syndrome are more common. Cushing’s disease has a male predominance in pre-pubertal children. Two causes of ACTH-independent Cushing’s syndrome, McCune-Albright syndrome and PPNAD, are typically diseases of childhood or young adults. Signs of virilisation in the very young (<4 years) suggest adrenal carcinoma. Ectopic secretion of ACTH occurs rarely in the pediatric population and is usually due to bronchial or thymic carcinoids (385).

As mentioned previously, late night salivary cortisol measurement has particular logistic benefits in children (101; 386). Serum midnight cortisol measurements in inpatients has high sensitivity (387). UFC should be corrected for body surface area (388). The standard 2-day LDDST adult protocol can be used in children weighing 40kg or more, otherwise the dexamethasone dose is adjusted to 30µg/kg/day (389). As in adults there is good correlation between the cortisol suppression on the LDDST and the HDDST for the differential diagnosis and thus the latter is not necessary (390). Although it can be argued that the ectopic ACTH syndrome is so rare in children that BIPSS is not necessary, it does add reassurance in those with a negative pituitary MRI, which is the case in more than 50% of cases. In addition, BIPSS has arguably better accuracy in lateralisation of the pituitary tumour (385). MRI is at least as useful as CT in the evaluation of adrenal causes (391).

Transsphenoidal surgery is the treatment of choice in children with Cushing's disease, with similar rates of remission as in adults (292). Conventional radiotherapy after non-curative transsphenoidal surgery performs even better than in adults, with reported remission rates as high as 100%, with remission occurring within 12 months (393). Following pituitary surgery, plus or minus radiotherapy, the incidence of growth hormone deficiency is high, but prompt diagnosis and treatment with human growth hormone ensure acceptable growth acceleration and catch-up growth, although an abnormal body composition often persists (394). Normalisation of reduced bone mineral density can also be achieved (395). Adrenalectomy is first-line therapy in ACTH-independent Cushing's syndrome.

**Cushing’s Syndrome in Pregnancy**

Cushing’s syndrome in pregnancy is fortunately rare, because ovulatory disorders and consequently infertility constitute the clinical picture in 75% of untreated patients with Cushing’s syndrome (292,293). The epidemiology in pregnant women is different to that in the non-pregnant population, in that pregnant patients show a 60% prevalence of ACTH-independent cases (48% percent adenoma and 10% carcinoma) followed by Cushing’s disease and bilateral adrenal hyperplasia, and rarely ectopic disease (292;293;396;397). The diagnosis is challenging because of the symptoms and signs common to both Cushing’s syndrome and normal physiological changes in pregnancy; such as weight gain, fatigue, striae, hypertension and glucose intolerance. In addition, the hormonal changes, which occur during pregnancy, may confuse the interpretation of the biochemical test procedures.

Total serum cortisol levels increase in pregnancy, as a result of induced production of corticosteroid-binding globulin by estrogens, beginning in the first trimester and peaking at 6 months, with a decrease only after delivery. Levels of free cortisol are also raised. In contrast to patients with pathologic hypercortisolism, levels of urinary 17-OH-corticosteroid excretion are within normal range and the cortisol diurnal rhythm is maintained, but with a higher nadir (396). UFC excretion is normal in the first trimester and then rises up to three-fold by term (398). Suppression to dexamethasone testing is blunted, especially after the first trimester (399). Plasma ACTH levels are slightly decreased in the beginning of the pregnancy, but later tends to rise, partially because of placental ACTH secretion.

In general, biochemical evaluation follows the same principles as with the non-pregnant patients. However, there are no agreed guidelines in interpreting results of hormonal measurements in pregnant Cushing’s patients, considering normal physiological deflection of cortisol metabolism in pregnant women. As mentioned, UFC excretion is normally increased, so if there is less than a 3-fold rise it cannot be diagnostic, and the dexamethasone response is blunted therefore cannot be used as screening test because of the possibility of a false positive result. Therefore, the differential diagnostis regarding the possible aetiology of Cushing’s syndrome can be quite demanding. If suppressed, levels of ACTH can point to adrenal origin, but lack of suppression does not eliminate possibility of ACTH-independent cause. High-dose dexamethasone test may be useful to distinguish adrenal cause, because women with adrenal causes tend to suppress, while those with Cushing’s disease do not (397;400-404).

As an initial evaluation the basal levels of ACTH and the high-dose dexamethasone test may be performed. Furthermore, due to the high prevalence of primary adrenal disease, it is reasonable to perform an abdominal ultrasound at an early stage.

The CRH test has also been used to identify patients with Cushing's disease, and there is no evidence of harm both in animal studies and the small number of pregnant patients studied with this drug.

MRI without gadolinium enhancement is considered safe in the third trimester, and its use in combination with the non-invasive tests above should be able to resolve most diagnostic issues. BIPSS with appropriate additional radiation protection for the fetus should be reserved only for cases where diagnostic uncertainty remains.

Maternal hypocortisolism is associated with 70% hypertension, preeclampsia, 25% diabetes mellitus, renal failure, and rarely death (292)

Although the fetus is partially protected from maternal hypercortisolism by placental 11-beta-hydroxisteroid dehydrogenase, which converts 85% of cortisol to inactive cortisone (405), the untreated condition is associated with miscarriage, premature delivery and neonatal adrenal insufficiency (292).

Because of both maternal and neonatal risk, definitive surgical treatment of adrenal or pituitary disease is recommended to achieve eucortisolemia. The second trimester is probably the safest time for adrenal surgery or transsphenoidal operation, although adverse fetal outcomes after the successful treatment may still persist, such as intrauterine growth restriction and premature birth, but it does prevent stillborn deliveries. (396)

Medical treatment carries potential risk to the fetus and should be considered only as second line therapy when the benefit outweighs the risk, and generally only as an interim measure to operation or awaiting the pituitary radiation effect. Metyrapone is probably the adrenolytic agent of choice, although an association with pre-eclampsia has been reported. Ketoconazole has been utilised successfully in a small number of patients but is teratogenic in animals and therefore should be used with caution.

**Prognosis and course after effective treatment**

Before treatment was readily available, the mortality rate for Cushing’s syndrome was 50% after the first symptoms appeared, mainly due to cardiovascular, thromboembolic, infectious or hypertensive complications (406)

Even today, patients with severe hypercortisolism can be fatally in jeopardised by increased coagulability consequences or opportunistic infections (95;407;408), emphasising the need for taking over the hormonal control as soon as possible. The prognosis is mainly a reflection of the underlying condition.

The life expectancy of patients with non-malignant causes of Cushing's syndrome has improved dramatically with effective surgical and medical treatments.

Even when cured by strict criteria, Cushing’s disease may often occur over time. (409).

From a number of studies in patients with Cushing’s disease treated in the era of transsphenoidal surgery, it initially appeared that after curative transsphenoidal surgery long-term mortality is not significantly different from that in the general population (23;401;408;411). However, another population based study suggested that mortality is marginally increased (3),while even more recently a very significantly increased mortality was shown even in patients who remained cured. This is perhaps not surprising given that while abdominal obesity may improve, hypertension and insulin resistance leading to increased cardiovascular risk with evidence of atherosclerotic disease persists when measured 5 years after remission of Cushing’s disease (77). It is therefore important to aggressively treat associated conditions such as hypertension and diabetes even when the Cushing’s per se has been controlled. Unlike some signs and symptoms that disappear gradually over the next year after successful treatment, co-morbidities such as diabetes mellitus and hypertension improve, but may not resolve completely, requiring further aggressive treatment. There is also some evidence that the outcome from Cushing's disease may be worse in males (412). Some of the signs and symptoms of Cushing’s syndrome are expected to disappear gradually over the following year after the treatment; skin thickness improves in weeks, but for some it may take longer, as does muscle strength.

The outcome of paediatric Cushing’s disease is excellent if treated at centres with appropriate experience (382; 413).

Cushing's syndrome results in significant impairment in quality of life (414), psychiatric symptoms (415) and cognitive deficits (416; 417), as previously noted. However, in general these are only partially improved with treatment, but often do not resolve completely in either children or adults

There is some evidence that deficits in bone mass may be partially reversed after treatment of hypercortisolaemia (418;419). Bisphosphonate treatment may induce a more rapid improvement in bone mineral density (420), and should be considered (along with calcium and vitamin D supplements), but it is unclear whether they are needed for the majority of patients with osteoporosis. Osteoporosis starts to improve after 6 months, with rapid improvement over the next two years, but with the possibility of residual disease to some extent (52;421-423). However, in general the prognosis is good without any specific treatment, and the care should be expectant.

The prognosis of the potentially malignant causes of Cushing's syndrome is more variable. Adrenal cancer associated with Cushing's syndrome has an extremely poor prognosis. Tumours that produce ectopic ACTH tend to have a poorer prognosis, compared with tumours from the same tissue that do not produce ACTH. Small cell lung cancer, islet cell tumours and thymic carcinoids (424) illustrate this phenomenon: up to 82% of patients with small cell lung cancer and Cushing’s syndrome were reported to die within 2 weeks from the start of chemotherapy (15), although currently a survival in terms of months should be expected.

References

1. **Newell-Price J, Trainer P, Besser M, Grossman A** 1998 The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19:647-672
2. **Ambrosi B, Faglia G** 1991 Epidemiology of pituitary tumours. In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (eds) Pituitary adenomas: New trends in basic and clinical research. Excerpta Medica, Amsterdam
3. **Etxabe J, Vazquez JA** 1994 Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 40:479-484
4. **Gicquel C, Le Bouc Y, Luton JP, Girard F, Bertagna X** 1992 Monoclonality of corticotroph macroadenomas in Cushing's disease. J Clin Endocrinol Metab 75:472-475
5. **Biller BM, Alexander JM, Zervas NT, Hedley-Whyte ET, Arnold A, Klibanski A** 1992 Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab 75:1303-1309
6. **Mampalam TJ, Tyrrell JB, Wilson CB** 1988 Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med 109:487-493
7. **Young WF, Jr., Scheithauer BW, Gharib H, Laws ER, Jr., Carpenter PC** 1988 Cushing's syndrome due to primary multinodular corticotrope hyperplasia. Mayo Clin Proc 63:256-262
8. **Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P** 2001 Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol 12:329-341
9. **Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, Horvath E, Kovacs K, Kuroki T, Young WF, Jr., Sebo TJ, Riehle DL, Belzberg AJ** 2002 Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg 96:352-360
10. **Dahia PL, Grossman AB** 1999 The molecular pathogenesis of corticotroph tumors. Endocr Rev 20:136-155
11. **Aron DC, Findling JW, Fitzgerald PA, Brooks RM, Fisher FE, Forsham PH, Tyrrell JB** 1981 Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature. Am J Med 71:302-306
12. **Doppman JI, Nieman LK, Travis WD, et al.** CT and MR imaging of massive macronodular adrenocortical disease: a rare cause of autonomus primary adrenal hypercortisolism. J Comp. Assist Tomogr. 1991; 15:773-779
13. **Samuels MH, Loriaux DL.** Cushing’s syndrome and the nodular adrenal gland. Endocrinol. Metab. Clin. North Am 1994; 23:555-569
14. **Sturrock ND, Morgan L, Jeffcoate WL**. Autunomous nodular hyperplasia of the adrenal cortex: tertiary hypercortisolism? Clin. Endocrinol (Oxf) 1995; 43753-758
15. **Dimopoulos MA, Fernandez JF, Samaan NA, Holoye PY, Vassilopoulou-Sellin R** 1992 Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer 69:66-71
16. **Odeli WD.** Ectopic ACTH secretion: a misnomer. Endocrinol. Metab. Clin. North Am. 1991; 20:371-379
17. **Ye L, Li X, Kong X, Wang W, Bi Y, Hu L, Cui B, Li X, Ning G** 2005 Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids. J Endocrinol 185:337-343
18. **Newell-Price J, King P, Clark AJ** 2001 The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and represses expression. Mol Endocrinol 15:338-348
19. **Clark AJ, Lavender PM, Besser GM, Rees LH** 1989 Pro-opiomelanocortin mRNA size heterogeneity in ACTH-dependent Cushing's syndrome. J Mol Endocrinol 2:3-9
20. **Stewart MF, Crosby SR, Gibson S, Twentyman PR, White A** 1989 Small cell lung cancer cell lines secrete predominantly ACTH precursor peptides not ACTH. Br J Cancer 60:20-24
21. **Oliver RL, Davis JR, White A** 2003 Characterisation of ACTH related peptides in ectopic Cushing's syndrome. Pituitary 6:119-126
22. **Shahani S, Nudelman RJ, Nalini R, Kim HS, Samson SL** 2010 Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature. Diagn Pathol 5:56
23. **Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J** 2001 Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab 86:117-123
24. **Invitti C, Giraldi FP, de Martin M, Cavagnini F** 1999 Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84:440-448
25. **Findlay JC, Sheeler LR, Engeland WC, Aron DC** 1993 Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 76:189-191
26. **Lacroix A, Bolte E, Tremblay J, Dupre J, Poitras P, Fournier H, Garon J, Garrel D, Bayard F, Taillefer R, .** 1992 Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing's syndrome. N Engl J Med 327:974-980
27. **Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, Lebrethon MC, Budi I, Balliere AM, Mahoudeau J** 1992 Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 327:981-986
28. **Christopoulos S, Bourdeau I, Lacroix A** 2004 Aberrant expression of hormone receptors in adrenal Cushing's syndrome. Pituitary 7:225-235
29. **De Groot JW, Links TP, Themmen AP, Looijenga LH, de Krijger RR, van Koetsveld PM, Hofland J, van den BG, Hofland LJ, Feelders RA** 2010 Aberrant expression of multiple hormone receptors in ACTH-independent macronodular adrenal hyperplasia causing Cushing's syndrome. Eur J Endocrinol 163:293-299
30. **Kirk JM, Brain CE, Carson DJ, Hyde JC, Grant DB** 1999 Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 134:789-792
31. **Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM** 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695
32. **Boston BA, Mandel S, LaFranchi S, Bliziotes M** 1994 Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab 79:890-893
33. **Travis WD, Tsokos M, Doppman JL, Nieman L, Chrousos GP, Cutler GB, Jr., Loriaux DL, Norton JA** 1989 Primary pigmented nodular adrenocortical disease. A light and electron microscopic study of eight cases. Am J Surg Pathol 13:921-930
34. **Stratakis CA, Boikos SA** 2007 Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab 3:748-757
35. **Swords FM, Baig A, Malchoff DM, Malchoff CD, Thorner MO, King PJ, Hunyady L, Clark AJ** 2002 Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol Endocrinol 16:2746-2753
36. **Maschler I, Rosenmann E, Ehrenfeld EN** 1979 Ectopic functioning adrenocortico-myelolipoma in longstanding Nelson's syndrome. Clin Endocrinol (Oxf) 10:493-497
37. **Lalau JD, Vieau D, Tenenbaum F, Westeel PF, Mesmacque A, Lenne F, Quichaud J** 1990 A case of pseudo-Nelson's syndrome: cure of ACTH hypersecretion by removal of a bronchial carcinoid tumor responsible for Cushing's syndrome. J Endocrinol Invest 13:531-537
38. **Adeyemi SD, Grange AO, Giwa-Osagie OF, Elesha SO** 1986 Adrenal rest tumour of the ovary associated with isosexual precocious pseudopuberty and cushingoid features. Eur J Pediatr 145:236-238
39. **Contreras P, Altieri E, Liberman C, Gac A, Rojas A, Ibarra A, Ravanal M, Seron-Ferre M** 1985 Adrenal rest tumor of the liver causing Cushing's syndrome: treatment with ketoconazole preceding an apparent surgical cure. J Clin Endocrinol Metab 60:21-28
40. **Marieb NJ, Spangler S, Kashgarian M, Heimann A, Schwartz ML, Schwartz PE** 1983 Cushing's syndrome secondary to ectopic cortisol production by an ovarian carcinoma. J Clin Endocrinol Metab 57:737-740
41. **Ross EJ, Linch DC**. Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2:646
42. **Wajchenberg BL, Bosco A, Marone MM, et al**. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab 1995; 80:2791
43. **Koch CA, Doppman JL, Watson JC, et al.** Spinal epidural lipomatosis in a patient with the ectopic corticotropin syndrome. N Engl J Med 1999; 341:1399.
44. **Panzer SW, Patrinely JR, Wilson HK**. Exophthalmos and iatrogenic Cushing's syndrome. Ophthal Plast Reconstr Surg 1994; 10:278
45. **Weber A, Trainer PJ, Grossman AB, Afshar F, Medbak S, Perry LA, Plowman PN, Rees LH, Besser GM, Savage MO** 1995 Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clin Endocrinol (Oxf) 43:19-28
46. **Ross EJ, Linch DC** 1982 Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 2:646-649
47. **Pecori GF, Pivonello R, Ambrogio AG, De Martino MC, de Martin M, Scacchi M, Colao A, Toja PM, Lombardi G, Cavagnini F** 2007 The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) 66:251-257
48. **Kaltsas G, Manetti L, Grossman AB** 2002 Osteoporosis in Cushing's syndrome. Front Horm Res 30:60-72
49. **Canalis E** Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. Clinical review 83. J Clin Metab. 1996; 81:3441-3447.
50. **Felson DT, Anderson JJ**. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet 1987; 1:902.
51. **Kristo C, Jemtland R, Ueland T, et al**. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol 2006; 154:109.
52. **Toth M, Grossman A.** Glucocorticoid – induced osteoporosis: lessons from Cushing’s syndrome Clin Endocrinol (Oxf) 2013 Jul; 79(1) :1-11 Epub
53. **Wajchenberg BL, Mendonca BB, Liberman B, Pereira MA, Carneiro PC, Wakamatsu A, Kirschner MA** 1994 Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 15:752-787
54. **Orth DN** 1995 Cushing's syndrome. N Engl J Med 332:791-803
55. **Luton JP, Thieblot P, Valcke JC, Mahoudeau JA, Bricaire H** 1977 Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab 45:488-495
56. **Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, Perry LA, Grossman AB, Besser GM, Trainer PJ** 1998 Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 83:3083-3088
57. **Kaltsas GA, Korbonits M, Isidori AM, Webb JA, Trainer PJ, Monson JP, Besser GM, Grossman AB** 2000 How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome? Clin Endocrinol (Oxf) 53:493-500
58. **Giustina A, Bossoni S, Bussi AR, Pozzi A, Wehrenberg WB** 1993 Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease. Endocr Res 19:47-56
59. **Bartalena L, Martino E, Petrini L, Velluzzi F, Loviselli A, Grasso L, Mammoli C, Pinchera A** 1991 The nocturnal serum thyrotropin surge is abolished in patients with adrenocorticotropin (ACTH)-dependent or ACTH-independent Cushing's syndrome. J Clin Endocrinol Metab 72:1195-1199
60. **Colao A, Pivonello R, Faggiano A, Filippella M, Ferone D, Di Somma C, Cerbone G, Marzullo P, Fenzi G, Lombardi G** 2000 Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf) 53:13-19
61. **Niepomniszcze H, Pitoia F, Katz SB, Chervin R, Bruno OD** 2002 Primary thyroid disorders in endogenous Cushing's syndrome. Eur J Endocrinol 147:305-311
62. **Stewart PM, Krozowski ZS** 1999 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 57:249-324
63. **Christy NP, Laragh JH** 1961 Pathogenesis of hypokalemic alkalosis in Cushing's syndrome. Nord Hyg Tidskr 265:1083-1088
64. **Biering H, Knappe G, Gerl H, Lochs H** 2000 [Prevalence of diabetes in acromegaly and Cushing syndrome]. Acta Med Austriaca 27:27-31
65. **Krassowski J, Godziejewska M, Kurta J, Kasperlik-Zaluska A** 1994 [Glucose tolerance in adrenocortical hyperfunction. Analysis of 100 cases]. Pol Arch Med Wewn 92:70-75
66. **Catargi B, Rigalleau V, Poussin A, Ronci-Chaix N, Bex V, Vergnot V, Gin H, Roger P, Tabarin A** 2003 Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab 88:5808-5813
67. **Leibowitz G, Tsur A, Chayen SD et al.** Pre-clinical Cushing syndrome: an unexpected poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf) 1996; 44:717
68. **Newsome S, Chen K, Hoang J, Wilson JD, Potter JM, Hickman PE** 2008 Cushing's syndrome in a clinic population with diabetes. Intern Med J 38:178-182
69. **Mullan K, Black N, Thiraviaraj A, Bell PM, Burgess C, Hunter SJ, McCance DR, Leslie H, Sheridan B, Atkinson AB** 2010 Is there value in routine screening for Cushing's syndrome in patients with diabetes? J Clin Endocrinol Metab 95:2262-2265
70. **Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM** 2008 The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526-1540
71. **Chiodini I, Morelli V, Salcuni AS, et al.** Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 2010; 95:2736.
72. **Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M** 2010 Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology 92 Suppl 1:86-90
73. **Neary NM, Booker OJ, Abel BS et al**. Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. J Clin Metab 2013; 98:2045
74. **Faser R, Davies DL, Connel JM.** Hormones and hypertension. Clin Endocrinol (Oxf). 1989; 31:701-746
75. **Torpy DJ, Mullen N, Ilias I, Nieman LK.** Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2002; 970:134.
76. **De Leo M, Pivonello R, Auriemma RS, Cozzolino A, Vitale P, Simeoli C, De Martino MC, Lombardi G, Colao A** 2010 Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology 92 Suppl 1:50-54
77. **Colao A, Pivonello R, Spiezia S et al.** Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84:2664-2672
78. **Faggiano A, Pivonello R, Spiezia S, et al.** Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88:2527.
79. **Jyotsna VP, Naseer A, Sreenivas V, Gupta N, Deepak KK** 2010 Effect of Cushing's syndrome - Endogenous hypercortisolemia on cardiovascular autonomic functions. Auton Neurosci
80. **Alexandraki KI, Kaltsas GA, Vouliotis AI, Papaioannou TG, Trisk L, Zilos A, Korbonits MÃ, Michael Besser G, Anastasakis A, Grossman AB** 2011 Specific electrocardiographic features associated with Cushing's disease. Clinical Endocrinology.
81. **Trementino L, Arnaldi G, Appolloni G, Daidone V, Scaroni C, Casonato A, Boscaro M** 2010 Coagulopathy in Cushing's syndrome. Neuroendocrinology 92 Suppl 1:55-59
82. **Stuijver DJ, Van Zaane B, Feelders RA et al.** Incidence of venous tromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 2011; 96:3525
83. **Sayegh F, Weigelin E**. Intraocular pressure in Cushing’s syndrome. Ophtalmics Res. 1975; 7:390-394
84. **Kelly W.** Exophthalmos in Cushing’s syndrome. Clin Endocrinol (Oxf) 1996; 45:167-170
85. **Bouzas EA, Mastorakos G, Friedman TC et al.** Posterior subcapsular catarct in endogenous Cushing’s syndrome: an uncommon manifestation. Invest Ophtalmol Vis Sci. 1993:34:3497-3500
86. **Haskett RF.** Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry 1985; 142:911.
87. **Kelly WF.** Psychiatric aspects of Cushing's syndrome. QJM 1996; 89:543.
88. **Born J, Späth-Schwalbe E, Schwakenhofer H, et al.** Influences of corticotropin-releasing hormone, adrenocorticotropin, and cortisol on sleep in normal man. J Clin Endocrinol Metab 1989; 68:904.
89. **Starkman MN, Gebarski SS, Berent S, Schteingart DE.** Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol Psychiatry 1992; 32:756.
90. **Forget H, Lacroix A, Somma M, Cohen H.** Cognitive decline in patients with Cushing's syndrome. J Int Neuropsychol Soc 2000; 6:20.
91. **Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr.** Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283.
92. **Auphan N, DiDonato JA, Rosette C, et al.** Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270:286.
93. **Jilma B, Stohlawetz P, Pernerstorfer T, et al.** Glucocorticoids dose-dependently increase plasma levels of granulocyte colony stimulating factor in man. J Clin Endocrinol Metab 1998; 83:1037.
94. **Graham BS, Tucker WS Jr.** Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med 1984; 101:334.
95. **Sarlis NJ, Chanock SJ, Nieman LK.** Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 2000; 85:42.
96. **Meinardi JR, Wolffenbuttel BH, Dullaart RP** 2007 Cyclic Cushing's syndrome: a clinical challenge. Eur J Endocrinol 157:245-254
97. **Carroll T, Raff H, Findling JW** 2009 Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis. Endocr Pract 15:335-342
98. **Liu H, Bravata DM, Cabaccan J, Raff H, Ryzen E** 2005 Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf) 63:642-649
99. **Raff H** 2009 Utility of salivary cortisol measurements in Cushing's syndrome and adrenal insufficiency. J Clin Endocrinol Metab 94:3647-3655
100. **Masserini B, Morelli V, Bergamaschi S, Ermetici F, Eller-Vainicher C, Barbieri AM, Maffini MA, Scillitani A, Ambrosi B, Beck-Peccoz P, Chiodini I** 2009 The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur J Endocrinol 160:87-92
101. **Martinelli CE, Jr., Sader SL, Oliveira EB, Daneluzzi JC, Moreira AC** 1999 Salivary cortisol for screening of Cushing's syndrome in children. Clin Endocrinol (Oxf) 51:67-71
102. **Castro M, Elias PC, Quidute AR, Halah FP, Moreira AC** 1999 Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 84:878-882
103. **Carrasco CA, Coste J, Guignat L, Groussin L, Dugue MA, Gaillard S, Bertagna X, Bertherat J** 2008 Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing's disease. J Clin Endocrinol Metab 93:4728-4734
104. **Nunes ML, Vattaut S, Corcuff JB, Rault A, Loiseau H, Gatta B, Valli N, Letenneur L, Tabarin A** 2009 Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients. J Clin Endocrinol Metab 94:456-462
105. **Nieman LK, Cutler GB, Jr.** 1990 The sensitivity of the urine free cortisol measurement as a screening test for Cushing's syndrome. Program of the 72nd Annual Meeting of The Endocrine Society, Atlanta GA (Abstract P-822)
106. **Corcuff JB, Tabarin A, Rashedi M, et al.** Overnight urinary free cortiso determination: a screening test for the diagnosis of Cushing’s syndrome. Clin Endocrinol (Oxf) 1998: 48:503-508
107. **Yanovski JA, Cutler GB, Jr., Chrousos GP, Nieman LK** 1993 Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 269:2232-2238
108. **Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA** 1976 Urinary free cortisol excretion in depression. Psychol Med 6:43-50
109. **Vila R, Granada ML, Guitierrez RM, Fernandez-Lopez JA, Remesar X, Formiguera X, Foz M, Alemany M** 2001 Urinary free cortisol excretion pattern in morbid obese women. Endocr Res 27:261-268
110. **Lin CL, Wu TJ, Machacek DA, Jiang NS, Kao PC** 1997 Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 82:151-155
111. **Turpeinen U, Markkanen H, Valimaki M, Stenman UH** 1997 Determination of urinary free cortisol by HPLC. Clin Chem 43:1386-1391
112. **Meikle AW, Findling J, Kushnir MM, Rockwood AL, Nelson GJ, Terry AH** 2003 Pseudo-Cushing Syndrome Caused by Fenofibrate Interference with Urinary Cortisol Assayed by High-Performance Liquid Chromatography. J Clin Endocrinol Metab 88:3521-3524
113. **Liddle GW** 1960 Tests of pituitary-adrenal suppressability in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 20:1539-1560
114. **Kennedy L, Atkinson AB, Johnston H, Sheridan B, Hadden DR** 1984 Serum cortisol concentrations during low dose dexamethasone suppression test to screen for Cushing's syndrome. Br Med J (Clin Res Ed) 289:1188-1191
115. **Hankin ME, Theile HM, Steinbeck AW** 1977 An evaluation of laboratory tests for the detection and differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 6:185-196
116. **Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M** 1995 A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 43:545-550
117. **Nugent CA, Nichols T, Tyler FH** 1965 Diagnosis of Cushing's syndrome-single dose dexamethasone suppression test. Arch Intern Med172-176
118. **Shimizu N, Yoshida H** 1976 Studies on the "low dose" suppressible Cushing's disease. Endocrinol Jpn 23:479-484
119. **McHardy-Young S, Harris PW, Lessof MH, Lyne C** 1967 Singledose dexamethasone suppression test for Cushing's syndrome. Br Med J 2:740-744
120. **Seidensticker JF, Folk RL, Wieland RG, Hamwi GJ** 1967 Screening test for Cushing's syndrome with plasma 11- hydroxycorticosteroids. JAMA 202:87-90
121. **Crapo L** 1979 Cushing's syndrome: a review of diagnostic tests. Metabolism 28:955-977
122. **Odagiri E, Demura R, Demura H, Suda T, Ishiwatari N, Abe Y, Jibiki K, Shizume K** 1988 The changes in plasma cortisol and urinary free cortisol by an overnight dexamethasone suppression test in patients with Cushing's disease. Endocrinol Jpn 35:795-802
123. **Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B** 1997 Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome--recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 34 ( Pt 3):222-229
124. **Stratakis CA, Sarlis N, Kirschner LS, Carney JA, Doppman JL, Nieman LK, Chrousos GP, Papanicolaou DA** 1999 Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Ann Intern Med 131:585-591
125. **Butler PW, Besser GM** 1968 Pituitary-adrenal function in severe depressive illness. Lancet 1:1234-1236
126. **Bernini GP, Argenio GF, Cerri F, Franchi F** 1994 Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions. J Endocrinol Invest 17:799-804
127. **Trainer PJ, Grossman A** 1991 The diagnosis and differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 34:317-330
128. **Papanicolaou DA, Yanovski JA, Cutler GB, Chrousos GP, Nieman LK,** A single midnight cortisol measurement discriminates Cushing's syndrome from pseudo-Cushing's states. (Abstract)
129. **Yanovski JA, Cutler GB, Jr., Chrousos GP, Nieman LK,** Prospective evaluation of the dexamethasone-suppressed corticotrophin-releasing hormone test in the differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. (Abstract)
130. **Nieman L** 2007 Editorial: The dexamethasone-suppressed corticotropin-releasing hormone test for the diagnosis of Cushing's syndrome: what have we learned in 14 years? J Clin Endocrinol Metab 92:2876-2878
131. **Van Cauter E, Refetoff S.** Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion. N Engl J Med 1985; 312:1343.
132. **Lytras N, Grossman A, Perry L, Tomlin S, Wass JA, Coy DH, Schally AV, Rees LH, Besser GM** 1984 Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary. Clin Endocrinol (Oxf) 20:71-84
133. **Fig LM, Gross MD, Shapiro B, Ehrmann DA, Freitas JE, Schteingart DE, Glazer GM, Francis IR** 1988 Adrenal localization in the adrenocorticotropic hormone-independent Cushing syndrome. Ann Intern Med 109:547-553
134. **Perry RR, Nieman LK, Cutler GB, Jr., Chrousos GP, Loriaux DL, Doppman JL, Travis WD, Norton JA** 1989 Primary adrenal causes of Cushing's syndrome. Diagnosis and surgical management. Ann Surg 210:59-68
135. **Doppman JL, Miller DL, Dwyer AJ, Loughlin T, Nieman L, Cutler GB, Chrousos GP, Oldfield E, Loriaux DL** 1988 Macronodular adrenal hyperplasia in Cushing disease. Radiology 166:347-352
136. **Blake MA, Kalra MK, Sweeney AT, et al.** Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 2006; 238:578.
137. **Doppman JL, Travis WD, Nieman L, Miller DL, Chrousos GP, Gomez MT, Cutler GB, Jr., Loriaux DL, Norton JA** 1989 Cushing syndrome due to primary pigmented nodular adrenocortical disease: findings at CT and MR imaging. Radiology 172:415-420
138. **Malchoff CD, Rosa J, DeBold CR, Kozol RA, Ramsby GR, Page DL, Malchoff DM, Orth DN** 1989 Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: an unusual cause of Cushing's syndrome. J Clin Endocrinol Metab 68:855-860
139. **Sohaib SA, Hanson JA, Newell-Price JD, Trainer PJ, Monson JP, Grossman AB, Besser GM, Reznek RH** 1999 CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing's syndrome. AJR Am J Roentgenol 172:997-1002
140. **Newell-Price J, Morris DG, Drake WM, Korbonits M, Monson JP, Besser GM, Grossman AB** 2002 Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 87:1640-1645
141. **Howlett TA, Drury PL, Perry L, Doniach I, Rees LH, Besser GM** 1986 Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf) 24:699-713
142. **Findling JW, Kehoe ME, Shaker JL, Raff H** 1991 Routine inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin (ACTH)-dependent Cushing's syndrome: early recognition of the occult ectopic ACTH syndrome. J Clin Endocrinol Metab 73:408-413
143. **Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, Cutler GB, Jr., Loriaux DL** 1991 Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 325:897-905
144. **Kaltsas GA, Giannulis MG, Newell-Price JD, Dacie JE, Thakkar C, Afshar F, Monson JP, Grossman AB, Besser GM, Trainer PJ** 1999 A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 84:487-492
145. **Colao A, Faggiano A, Pivonello R, Giraldi FP, Cavagnini F, Lombardi G** 2001 Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. Eur J Endocrinol 144:499-507
146. **Swearingen B, Katznelson L, Miller K, Grinspoon S, Waltman A, Dorer DJ, Klibanski A, Biller BM** 2004 Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab 89:3752-3763
147. **Yamamoto Y, Davis DH, Nippoldt TB, Young WF, Jr., Huston J, III, Parisi JE** 1995 False-positive inferior petrosal sinus sampling in the diagnosis of Cushing's disease. Report of two cases. J Neurosurg 83:1087-1091
148. **McCance DR, McIlrath E, McNeill A, Gordon DS, Hadden DR, Kennedy L, Sheridan B, Atkinson AB** 1989 Bilateral inferior petrosal sinus sampling as a routine procedure in ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 30:157-166
149. **Machado MC, de Sa SV, Domenice S, Fragoso MC, Puglia P, Jr., Pereira MA, de Mendonca BB, Salgado LR** 2007 The role of desmopressin in bilateral and simultaneous inferior petrosal sinus sampling for differential diagnosis of ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 66:136-142
150. **Miller DL** 1992 Neurologic complications of petrosal sinus sampling. Radiology 183:878
151. **Lefournier V, Gatta B, Martinie M, Vasdev A, Tabarin A, Bessou P, Berge J, Bachelot I, Chabre O** 1999 One transient neurological complication (sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 84:3401-3402
152. **Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M** 2003 Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593-5602
153. **Rotman-Pikielny P, Patronas N, Papanicolaou DA** 2003 Pituitary apoplexy induced by corticotrophin-releasing hormone in a patient with Cushing's disease. Clin Endocrinol (Oxf) 58:545-549
154. **Erickson D, Huston J, III, Young WF, Jr., Carpenter PC, Wermers RA, Bonelli FS, Powell CC** 2004 Internal jugular vein sampling in adrenocorticotropic hormone-dependent Cushing's syndrome: a comparison with inferior petrosal sinus sampling. Clin Endocrinol (Oxf) 60:413-419
155. **Tabarin A, Greselle JF, San Galli F, Leprat F, Caille JM, Latapie JL, Guerin J, Roger P** 1991 Usefulness of the corticotropin-releasing hormone test during bilateral inferior petrosal sinus sampling for the diagnosis of Cushing's disease. J Clin Endocrinol Metab 73:53-59
156. **Landolt AM, Schubiger O, Maurer R, Girard J** 1994 The value of inferior petrosal sinus sampling in diagnosis and treatment of Cushing's disease. Clin Endocrinol (Oxf) 40:485-492
157. **Lefournier V, Martinie M, Vasdev A, Bessou P, Passagia JG, Labat-Moleur F, Sturm N, Bosson JL, Bachelot I, Chabre O** 2003 Accuracy of bilateral inferior petrosal or cavernous sinuses sampling in predicting the lateralization of Cushing's disease pituitary microadenoma: influence of catheter position and anatomy of venous drainage. J Clin Endocrinol Metab 88:196-203
158. **Lienhardt A, Grossman AB, Dacie JE, Evanson J, Huebner A, Afshar F, Plowman PN, Besser GM, Savage MO** 2001 Relative contributions of inferior petrosal sinus sampling and pituitary imaging in the investigation of children and adolescents with ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 86:5711-5714
159. **Morris DG, Grossman AB** 2003 Dynamic tests in the diagnosis and differential diagnosis of Cushing's syndrome. J Endocrinol Invest 26:64-73
160. **Miller DL, Doppman JL, Nieman LK, Cutler GB, Jr., Chrousos G, Loriaux DL, Oldfield EH** 1990 Petrosal sinus sampling: discordant lateralization of ACTH-secreting pituitary microadenomas before and after stimulation with corticotropin-releasing hormone. Radiology 176:429-431
161. **Strott CA, Nugent CA, Tyler FH.** Cushing's syndrome caused by bronchial adenomas. Am J Med 1968; 44:97.
162. **Malchoff CD, Orth DN, Abboud C, et al.** Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med 1988; 84:760.
163. **Dichek HL, Nieman LK, Oldfield EH, et al.** A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1994; 78:418.
164. **Howlett TA, Grossman A, Rees LH, Besser GM** 1986 Differential diagnosis of Cushing's syndrome. Lancet 2:871
165. **Nieman LK, Chrousos GP, Oldfield EH, Avgerinos PC, Cutler GB, Jr., Loriaux DL** 1986 The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome. Ann Intern Med 105:862-867
166. **Grossman AB, Howlett TA, Perry L, Coy DH, Savage MO, Lavender P, Rees LH, Besser GM** 1988 CRF in the differential diagnosis of Cushing's syndrome: a comparison with the dexamethasone suppression test. Clin Endocrinol (Oxf) 29:167-178
167. **Tyrrell JB, Findling JW, Aron DC, Fitzgerald PA, Forsham PH** 1986 An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. Ann Intern Med 104:180-186
168. **Bruno OD, Rossi MA, Contreras LN, Gomez RM, Galparsoro G, Cazado E, Kral M, Leber B, Arias D** 1985 Nocturnal high-dose dexamethasone suppression test in the aetiological diagnosis of Cushing's syndrome. Acta Endocrinol (Copenh) 109:158-162
169. **Isidori AM, Kaltsas GA, Mohammed S, Morris DG, Jenkins P, Chew SL, Monson JP, Besser GM, Grossman AB** 2003 Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 88:5299-5306
170. **Trainer PJ, Faria M, Newell-Price J, Browne P, Kopelman P, Coy DH, Besser GM, Grossman AB** 1995 A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. J Clin Endocrinol Metab 80:412-417
171. **Trainer PJ, Woods RJ, Korbonits M, Popovic V, Stewart PM, Lowry PJ, Grossman AB** 1998 The pathophysiology of circulating corticotropin-releasing hormone- binding protein levels in the human. J Clin Endocrinol Metab 83:1611-1614
172. **Nieman LK, Oldfield EH, Wesley R, Chrousos GP, Loriaux DL, Cutler GB, Jr.** 1993 A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 77:1308-1312
173. **Giraldi FP, Invitti C, Cavagnini F** 2001 The corticotropin-releasing hormone test in the diagnosis of ACTH- dependent Cushing's syndrome: a reappraisal. Clin Endocrinol (Oxf) 54:601-607
174. **Hermus AR, Pieters GF, Pesman GJ, Smals AG, Benraad TJ, Kloppenborg PW** 1986 The corticotropin-releasing-hormone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome. Lancet 2:540-544
175. **Woo YS, Isidori AM, Wat WZ, Kaltsas GA, Afshar F, Sabin I, Jenkins PJ, Monson JP, Besser GM, Grossman AB** 2005 Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 90:4963-4969
176. **Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM, Trainer PJ** 1999 The growth hormone secretagogue hexarelin stimulates the hypothalamo- pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 84:2489-2495
177. **Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K, Grossman AB** 2001 The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 86:881-887
178. **Tabarin A, San Galli F, Dezou S, Leprat F, Corcuff JB, Latapie JL, Guerin J, Roger P** 1990 The corticotropin-releasing factor test in the differential diagnosis of Cushing's syndrome: a comparison with the lysine-vasopressin test. Acta Endocrinol (Copenh) 123:331-338
179. **Malerbi DA, Mendonca BB, Liberman B, Toledo SP, Corradini MC, Cunha-Neto MB, Fragoso MC, Wajchenberg BL** 1993 The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 38:463-472
180. **Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R, Lombardi G, Camanni F** 1997 Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 82:2439-2444
181. **Newell-Price J, Perry L, Medbak S, Monson J, Savage M, Besser M, Grossman A** 1997 A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 82:176-181
182. **Tsagarakis S, Tsigos C, Vasiliou V, Tsiotra P, Kaskarelis J, Sotiropoulou C, Raptis SA, Thalassinos N** 2002 The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. J Clin Endocrinol Metab 87:1646-1653
183. **Korbonits M, Jacobs RA, Aylwin SJB, Burrin JM, Dahia PLM, Monson JP, Honegger J, Fahlbush R, Trainer PJ, Chew SL, Besser GM, Grossman AB** 1998 Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors. J Clin Endocrinol Metab 83:3624-3630
184. **Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH** 1994 Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120:817-820
185. **Doppman JL, Frank JA, Dwyer AJ, Oldfield EH, Miller DL, Nieman LK, Chrousos GP, Cutler GB, Jr., Loriaux DL** 1988 Gadolinium DTPA enhanced MR imaging of ACTH-secreting microadenomas of the pituitary gland. J Comput Assist Tomogr 12:728-735
186. **Patronas N, Bulakbasi N, Stratakis CA, Lafferty A, Oldfield EH, Doppman J, Nieman LK** 2003 Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab 88:1565-1569
187. **Tabarin A, Laurent F, Catargi B, et al.** Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease. Clin Endocrinol (Oxf) 1998; 49:293.
188. **Findling JW, Doppman JL** 1994 Biochemical and radiologic diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am 23:511-537
189. **Kaye TB, Crapo L** 1990 The Cushing syndrome: an update on diagnostic tests. Ann Intern Med 112:434-444
190. **Escourolle H, Abecassis JP, Bertagna X, Guilhaume B, Pariente D, Derome P, Bonnin A, Luton JP** 1993 Comparison of computerized tomography and magnetic resonance imaging for the examination of the pituitary gland in patients with Cushing's disease. Clin Endocrinol (Oxf) 39:307-313
191. **De Herder WW, Uitterlinden P, Pieterman H, Tanghe HL, Kwekkeboom DJ, Pols HA, Singh R, van de Berge JH, Lamberts SW** 1994 Pituitary tumour localization in patients with Cushing's disease by magnetic resonance imaging. Is there a place for petrosal sinus sampling? Clin Endocrinol (Oxf) 40:87-92
192. **Buchfelder M, Nistor R, Fahlbusch R, Huk WJ** 1993 The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropic hormone-secreting adenomas in Cushing disease. AJNR Am J Neuroradiol 14:1183-1190
193. **Doppman JL, Pass HI, Nieman LK, Findling JW, Dwyer AJ, Feuerstein IM, Ling A, Travis WD, Cutler GB, Jr., Chrousos GP, .** 1991 Detection of ACTH-producing bronchial carcinoid tumors: MR imaging vs CT. AJR Am J Roentgenol 156:39-43
194. **De Herder WW, Lamberts SW** 1999 Tumor localization--the ectopic ACTH syndrome. J Clin Endocrinol Metab 84:1184-1185
195. **Tabarin A, Valli N, Chanson P, Bachelot Y, Rohmer V, Bex-Bachellerie V, Catargi B, Roger P, Laurent F** 1999 Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 84:1193-1202
196. **Torpy DJ, Chen CC, Mullen N, Doppman JL, Carrasquillo JA, Chrousos GP, Nieman LK** 1999 Lack of utility of (111) In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab 84:1186-1192
197. **Kumar J, Spring M, Carroll PV, Barrington SF, Powrie JK** 2006 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol (Oxf) 64:371-374
198. **Pacak K, Ilias I, Chen CC, Carrasquillo JA, Whatley M, Nieman LK** 2004 The role of [(18) F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. J Clin Endocrinol Metab 89:2214-2221
199. **Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M** 2008 Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement. J Clin Endocrinol Metab 93:2454-2462
200. **Lamberts SW, van der Lely AJ, de Herder WW** 1995 Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and the long-term follow-up. J Clin Endocrinol Metab 80:3111-3113
201. **Netea-Maier RT, van Lindert EJ, den Heijer M, van der EA, Pieters GF, Sweep CG, Grotenhuis JA, Hermus AR** 2006 Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease. Eur J Endocrinol 154:675-684
202. **Wagenmakers MA, Netea-Maier RT, van Lindert EJ, Timmers HJ, Grotenhuis JA, Hermus AR** 2009 Repeated transsphenoidal pituitary surgery (TS) via the endoscopic technique: a good therapeutic option for recurrent or persistent Cushing's disease (CD). Clin Endocrinol (Oxf) 70:274-280
203. **Atkinson AB, Kennedy A, Wiggam MI, et al**. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 2005; 63:549
204. **Bochicchio D, Losa M, Buchfelder M** 1995 Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 80:3114-3120
205. **Blevins LS, Jr., Christy JH, Khajavi M, Tindall GT** 1998 Outcomes of therapy for Cushing's disease due to adrenocorticotropin- secreting pituitary macroadenomas. J Clin Endocrinol Metab 83:63-67
206. **Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, Savage MO, Afshar F, Besser GM** 1993 Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol (Oxf) 38:73-78
207. **Hughes NR, Lissett CA, Shalet SM** 1999 Growth hormone status following treatment for Cushing's syndrome. Clin Endocrinol (Oxf) 51:61-66
208. **Kelly DF.** Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's Syndrome. Neurosurg Focus 2007; 23:E5
209. **Bakiri F, Tatai S, Aouali R, et al.** Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery: prognosis factors and long-term follow-up. J Endocrinol Invest 1996; 19:572.
210. **Prevedello DM, Pouratian N, Sherman J, et al.** Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg 2008; 109:751
211. **Mason RB, Nieman LK, Doppman JL, Oldfield EH.** Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function. J Neurosurg 1997; 87:343
212. **Kammer H, George R.** Cushing's disease in a patient with an ectopic pituitary adenoma. JAMA 1981; 246:2722.
213. **Wilson CB, Mindermann T, Tyrrell JB.** Extrasellar, intracavernous sinus adrenocorticotropin-releasing adenoma causing Cushing's disease. J Clin Endocrinol Metab 1995; 80:1774
214. **Weil RJ, Vortmeyer AO, Nieman LK, et al.** Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing's disease. J Clin Endocrinol Metab 2006; 91:2656
215. **Meij BP, Lopes MB, Ellegala DB, et al**. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 2002; 96:195
216. **Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M** 1996 Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 81:2647-2652
217. **Streeten DH, Anderson GH Jr, Dalakos T, Joachimpillai AD**. Intermittent hypercortisolism: a disorder strikingly prevalent after hypophysial surgical procedures. Endocr Pract 1997; 3:123
218. **Estrada J, García-Uría J, Lamas C, et al.** The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 2001; 86:5695
219. **Kelly PA, Samandouras G, Grossman AB, Afshar F, Besser GM, Jenkins PJ** 2002 Neurosurgical Treatment of Nelson's Syndrome. J Clin Endocrinol Metab 87:5465-5469
220. **McCance DR, Besser M, Atkinson AB**. Assessment of cure after transsphenoidal surgery for Cushing's disease. Clin Endocrinol (Oxf) 1996; 44:1
221. **Newell-Price J.** Transsphenoidal surgery for Cushing's disease: defining cure and following outcome. Clin Endocrinol (Oxf) 2002; 56:19
222. **Yap LB, Turner HE, Adams CB, Wass JA.** Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin Endocrinol (Oxf) 2002; 56:25
223. **Pereira AM, van Aken MO, van Dulken H, et al.** Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab 2003; 88:5858.
224. **Esposito F, Dusick JR, Cohan P, Moftakhar P, McArthur D, Wang C, Swerdloff RS, Kelly DF** 2006 Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 91:7-13
225. **Valassi E, Biller BM, Swearingen B, et al.** Delayed remission after transsphenoidal surgery in patients with Cushing's disease. J Clin Endocrinol Metab 2010; 95:601
226. **Ram Z, Nieman LK, Cutler GB, Jr., Chrousos GP, Doppman JL, Oldfield EH** 1994 Early repeat surgery for persistent Cushing's disease. J Neurosurg 80:37-45
227. **Locatelli M, Vance ML, Laws ER** 2005 Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 90:5478-5482
228. **Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP** 1996 Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab 81:2303-2306
229. **Leshin M** 1982 Acute adrenal insufficiency: recognition, management, and prevention. Urol Clin North Am 9:229-235
230. **Doherty GM, Nieman LK, Cutler GB, Jr., Chrousos GP, Norton JA** 1990 Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing's syndrome. Surgery 108:1085-1090
231. **Plumpton FS, Besser GM** 1968 The adrenocortical response to surgery and insulin-induced hypoglycemia in corticosteroid-treated and normal subjects. Br J Surg 55:857
232. **Bangar V, Clayton RN** 1998 How reliable is the short synacthen test for the investigation of the hypothalamic-pituitary-adrenal axis? Eur J Endocrinol 139:580-583
233. **Kehlet H, Lindholm J, Bjerre P** 1984 Value of the 30 min ACTH-test in assessing hypothalamic-pituitary-adrenocortical function after pituitary surgery in Cushing's disease. Clin Endocrinol (Oxf) 20:349-353
234. **Stewart PM, Corrie J, Seckl JR, Edwards CR, Padfield PL** 1988 A rational approach for assessing the hypothalamo-pituitary-adrenal axis. Lancet 1:1208-1210
235. **Orme SM, Peacey SR, Barth JH, Belchetz PE** 1996 Comparison of tests of stress-released cortisol secretion in pituitary disease. Clin Endocrinol (Oxf) 45:135-140
236. **Ammari F, Issa BG, Millward E, Scanion MF** 1996 A comparison between short ACTH and insulin stress tests for assessing hypothalamo-pituitary-adrenal function. Clin Endocrinol (Oxf) 44:473-476
237. **Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ** 2009 Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 94:1548-1554
238. **Timmers HJ, van Ginneken EM, Wesseling P, Sweep CG, Hermus AR** 2006 A patient with recurrent hypercortisolism after removal of an ACTH-secreting pituitary adenoma due to an adrenal macronodule. J Endocrinol Invest 29:934-939
239. **Olson BR, Rubino D, Gumowski J, Oldfield EH** 1995 Isolated hyponatremia after transsphenoidal pituitary surgery. J Clin Endocrinol Metab 80:85-91
240. **Nemergut EC, Zuo Z, Jane JA Jr, Laws ER Jr.** Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. J Neurosurg 2005; 103:448
241. **Burke CW, Adams CB, Esiri MM, et al.** Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome? Clin Endocrinol (Oxf) 1990; 33:525
242. **Kemink L, Pieters G, Hermus A, Smals A, Kloppenborg P** 1994 Patient's age is a simple predictive factor for the development of Nelson's syndrome after total adrenalectomy for Cushing's disease. J Clin Endocrinol Metab 79:887-889
243. **Jenkins PJ, Trainer PJ, Plowman PN, Shand WS, Grossman AB, Wass JA, Besser GM** 1995 The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 80:165-171
244. **Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X** 2007 Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab 92:172-179
245. **Nagesser SK, van Seters AP, Kievit J, Hermans J, van Dulken H, Krans HM, van de Velde CJ** 2000 Treatment of pituitary-dependent Cushing's syndrome: long-term results of unilateral adrenalectomy followed by external pituitary irradiation compared to transsphenoidal pituitary surgery. Clin Endocrinol (Oxf) 52:427-435
246. **Devoe DJ, Miller WL, Conte FA, et al.** Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997; 82:3196
247. **Jennings AS, Liddle GW, Orth DN.** Results of treating childhood Cushing's disease with pituitary irradiation. N Engl J Med 1977; 297:957
248. **Johnson DH, Greco FA.** Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986; 58:2198
249. **Salassa RM, Kearns TP, Kernohan JW,** et al. Pituitary tumors in patients with Cushing's syndrome. J Clin Endocrinol Metab 1959; 19:1523.
250. **Nelson DH, Meakin JW, Thorn GW.** ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome. Ann Intern Med 1960; 52:560
251. **Howlett TA, Plowman PN, Wass JA, Rees LH, Jones AE, Besser GM** 1989 Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up. Clin Endocrinol (Oxf) 31:309-323
252. **Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T, Barcelo B** 1997 The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 336:172-177
253. **Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi ER** 2007 Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neurooncol 84:79-84
254. **Orth DN, Liddle GW.** Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971; 285:243
255. **Brada M, Ashley S, Ford D, et al.** Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf) 2002; 57:713
256. **Erfurth EM, Bülow B, Svahn-Tapper G, et al.** Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 2002; 87:4892
257. **Plowman PN** 1999 Pituitary adenoma radiotherapy-when, who and how? Clin Endocrinol (Oxf) 51:265-271
258. **Vance ML** 2009 Cushing's disease: radiation therapy. Pituitary 12:11-14
259. **Sheline GE, Wara WM, Smith V** 1980 Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6:1215-1228
260. **Mitsumori M, Shrieve DC, Alexander E 3rd, et al.** Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 1998; 42:573.
261. **Landolt AM, Haller D, Lomax N, et al.** Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998; 88:1002.
262. **Höybye C, Grenbäck E, Rähn T, et al.** Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 2001; 49:284.
263. **Jagannathan J, Sheehan JP, Pouratian N, et al**. Gamma Knife surgery for Cushing's disease. J Neurosurg 2007; 106:980
264. **Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML** 2007 Gamma Knife surgery for Cushing's disease. J Neurosurg 106:980-987
265. **Swords FM, Monson JP, Besser GM, Chew SL, Drake WM, Grossman AB, Plowman PN** 2009 Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy. Eur J Endocrinol 161:819-828
266. **Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, Ancukiewicz M, Bussiere M, Klibanski A, Loeffler JS** 2008 Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 93:393-399
267. **Swords FM, Allan CA, Plowman PN, Sibtain A, Evanson J, Chew SL, Grossman AB, Besser GM, Monson JP** 2003 Stereotactic Radiosurgery XVI: A Treatment for Previously Irradiated Pituitary Adenomas. J Clin Endocrinol Metab 88:5334-5340
268. **He J, Zhou J, Lu Z** 1995 Radiotherapy of ectopic ACTH syndrome due to thoracic carcinoids. Chin Med J (Engl ) 108:338-341
269. **Andres R, Mayordomo JI, Cajal S, Tres A** 2002 Paraneoplastic Cushing's syndrome associated to locally advanced thymic carcinoid tumor. Tumori 88:65-67
270. **Ilias I, Torpy DJ, Pacak K, et al.** Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90:4955.
271. **Isidori AM, Kaltsas GA, Pozza C, et al.** The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 2006; 91:371.
272. **Miller CA, Ellison EC.** Therapeutic alternatives in metastatic neuroendocrine tumors. Surg Oncol Clin N Am 1998; 7:863.
273. **Lehnert T.** Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 1998; 66:1307.
274. **Tabarin A, Catargi B, Chanson P, et al.** Pseudo-tumours of the thymus after correction of hypercortisolism in patients with ectopic ACTH syndrome: a report of five cases. Clin Endocrinol (Oxf) 1995; 42:207.
275. **Ur E, Grossman A.** Corticotropin-releasing hormone in health and disease: an update. Acta Endocrinol (Copenh) 1992; 127:193.
276. **Ogura M, Kusaka I, Nagasaka S et al.** Unilateral adrenalectomy improves insulin resistance and diabetes mellitus in a petient with ACTH independent macronodular adrenal hyperplasia Endocr J 2003; 50:715
277. **Lamas C, Alfarro JJ, Lucas T et al.** Is unilateral adrenalectomy an alternative treatment for ACTH independent macronodular adrenal hyperplasia ? Long term follow up of four cases. Eur J Endocrinol 2002; 146:237
278. **Lacroix A, Hamet P., Boutin JM.** Leuprolide acetate therapy in luteinizating hormone-dependant Cushing’s syndrome N Eng J Med 1999; 341:1577
279. **Lacroix A, Tremblay J, Rousseau G et al.** Propranolol therapy for ectopic beta adrenergic receptors in adrenal Cushing’s syndrome N Eng J Med 1997; 337:1429
280. **Valimaki M, Pelkonen R, Porkka L, Sivula A, Kahri A** 1984 Long-term results of adrenal surgery in patients with Cushing's syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 20:229-236
281. **Sarkar R, Thompson NW, McLeod MK** 1990 The role of adrenalectomy in Cushing's syndrome. Surgery 108:1079-1084
282. **McCallum RW, Connell JM** 2001 Laparoscopic adrenalectomy. Clin Endocrinol (Oxf) 55:435-436
283. **Bertagna C, Orth DN** 1981 Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 71:855-875
284. **Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, Favia G, Borrelli D, Boffi L, Capussotti L, Carbone G, Casaccia M, Cavallaro A, Del Gaudio A, Dettori G, Di G, V, Mazziotti A, Marrano D, Masenti E, Miccoli P, Mosca F, Mussa A, Petronio R, Piat G, Marazano L, .** 1997 Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 122:1212-1218
285. **Magee BJ, Gattamaneni HR, Pearson D** 1987 Adrenal cortical carcinoma: survival after radiotherapy. Clin Radiol 38:587-588
286. **De Castro F, Isa W, Aguera L, Rosell CD, Abad JI, Robles JE, Zudaire JJ, Berian JM** 1993 [Primary adrenal carcinoma]. Actas Urol Esp 17:30-34
287. **Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, Allolio B** 2006 Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91:4501-4504
288. **Carballeira A, Fishman LM, Jacobi JD** 1976 Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: correlation of in vivo and in vitro studies. J Clin Endocrinol Metab 42:687-695
289. **Trainer PJ, Besser M** 1994 Cushing's syndrome. Therapy directed at the adrenal glands. Endocrinol Metab Clin North Am 23:571-584
290. **Owen LJ, Halsall DJ, Keevil BG** 2010 Cortisol measurement in patients receiving metyrapone therapy. Ann Clin Biochem 47:573-575
291. **Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser GM** 1991 Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 35:169-178
292. **Aron DC, Schnall AM, Sheeler LR.** Cushing's syndrome and pregnancy. Am J Obstet Gynecol 1990; 162:244.
293. **Buescher MA, McClamrock HD, Adashi EY.** Cushing syndrome in pregnancy. Obstet Gynecol 1992; 79:130
294. **Schteingart DE.** Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs 2009; 14:661.
295. **Feelders RA, Hofland LJ, de Herder WW.** Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology 2010; 92 Suppl 1:111
296. **Connell JM, Cordiner J, Davies DL, Fraser R, Frier BM, McPherson SG** 1985 Pregnancy complicated by Cushing's syndrome: potential hazard of metyrapone therapy. Case report. Br J Obstet Gynaecol 92:1192-1195
297. **Santen RJ, Van den BH, Symoens J, Brugmans J, DeCoster R** 1983 Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 57:732-736
298. **Pont A, Goldman ES, Sugar AM, Siiteri PK, Stevens DA** 1985 Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med 145:1429-1431
299. **Engelhardt D, Dorr G, Jaspers C, Knorr D** 1985 Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klin Wochenschr 63:607-612
300. **Engelhardt D, Weber MM, Miksch T, Abedinpour F, Jaspers C** 1991 The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin Endocrinol (Oxf) 35:163-168
301. **Steen RE, Kapelrud H, Haug E, Frey H** 1991 In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour. Acta Endocrinol (Copenh) 125:331-334
302. **Chou SC, Lin JD** 2000 Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing's disease. Endocr J 47:401-406
303. **Ahmed M, Kanaan I, Alarifi A, Ba-Essa E, Saleem M, Tulbah A, McArthur P, Hessler R** 2000 ACTH-producing pituitary cancer: experience at the King Faisal Specialist Hospital & Research Centre. Pituitary 3:105-112
304. **Rickman T, Garmany R, Doherty T, Benson D, Okusa MD** 2001 Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma. Am J Kidney Dis 37:838-846
305. **Amado JA, Pesquera C, Gonzalez EM, et al.** Successful treatment with ketoconazole of Cushing's syndrome in pregnancy. Postgrad Med J 1990; 66:221.
306. **Berwaerts J, Verhelst J, Mahler C, Abs R.** Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol 1999; 13:175.
307. **McCance DR, Hadden DR, Kennedy L, et al.** Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1987; 27:593.
308. **Castinetti F, Guignat L, Giraud P, et al.** Ketoconazole in Cushing's disease: is it worth a try? J Clin Endocrinol Metab 2014; 99:1623.
309. **Lewis JH, Zimmerman HJ, Benson GD, Ishak KG** 1984 Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86:503-513
310. **McCance DR, Ritchie CM, Sheridan B, Atkinson AB** 1987 Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1:573
311. **Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D** 1991 Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 35:347-352
312. **Tucker WS, Jr., Snell BB, Island DP, Gregg CR** 1985 Reversible adrenal insufficiency induced by ketoconazole. JAMA 253:2413-2414
313. **Miettinen TA** 1988 Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res 29:43-51
314. **Van der Pas R, Hofland LJ, Hofland J, et al.** Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol 2012; 215:403.
315. **Ledingham IM, Watt I** 1983 Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1:1270
316. **Weber MM, Lang J, Abedinpour F, Zeilberger K, Adelmann B, Engelhardt D** 1993 Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis. Clin Investig 71:933-938
317. **Lamberts SW, Bons EG, Bruining HA, de Jong FH** 1987 Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther 240:259-264
318. **De Coster R, Beerens D, Haelterman C, Wouters L** 1985 Effects of etomidate on cortisol biosynthesis in isolated guinea-pig adrenal cells: comparison with metyrapone. J Endocrinol Invest 8:199-202
319. **Allolio B, Stuttmann R, Fischer H, Leonhard W, Winkelmann W** 1983 Long-term etomidate and adrenocortical suppression. Lancet 2:626
320. **Allolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hancke C, Winkelmann W** 1988 Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr 66:361-364
321. **Herrmann BL, Mitchell A, Saller B, Stolke D, Forsting M, Frilling A, Mann K** 2001 [Transsphenoidal hypophysectomy of a patient with an ACTH-producing pituitary adenoma and an "empty sella" after pretreatment with etomidate]. Dtsch Med Wochenschr 126:232-234
322. **Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM** 1998 Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab 83:3542-3544
323. **Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK** 2001 Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab 86:4104-4108
324. **Greening JE, Brain CE, Perry LA, Mushtaq I, Sales MJ, Grossman AB, Savage MO** 2005 Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res 64:140-143
325. **Preda VA, Sen J, Karavitaki N, Grossman AB.** Etomidate in the menagement of hypercortisolemia in Cushing’s syndrome: a review. Eur J Endocrinolo. 2012 August; 167(2):137-43 Epub
326. **Schulte HM, Benker G, Reinwein D, et al.** Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990; 70:1426
327. **Young RB, Bryson MJ, Sweat ML, Street JC** 1973 Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem 4:585-591
328. **Nelson Aa, Woodard G.** Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE). Arch Pathol (Chic) 1949; 48:387.
329. **Cueto C, Brown JH, Richardson AP Jr.** Biological studies on an adrenocorticolytic agent and the isolation of the active components. Endocrinology 1958; 62:334.
330. **Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C** 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891-897
331. **Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A** 2007 Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372-2380
332. **Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, .** 1990 Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195-1201
333. **Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA** 1980 Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 92:613-619
334. **Leiba S, Weinstein R, Shindel B, et al.** The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 1989; 50:49
335. **Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM** 1992 Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia. Q J Med 84:671-679
336. **Haak HR, Caekebeke-Peerlinck KM, van Seters AP, Briet E** 1991 Prolonged bleeding time due to mitotane therapy. Eur J Cancer 27:638-641
337. **Hogan TF, Citrin DL, Johnson BM, et al.** o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer 1978; 42:2177.
338. **Vilar O, Tullner Ww.** Effects of o,p' DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology 1959; 65:80.
339. **Lamberts SW, de Herder WW, Krenning EP, Reubi JC** 1994 A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. J Clin Endocrinol Metab 78:17-19
340. **Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A** 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482-4488
341. **Hofland LJ, van der Hoek J, Feelders R, et al.** The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005; 152:645.
342. **Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J** 2009 Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115-122
343. **Colao A** 2010 Pasireotide (SOM230) provides clinical benefit in patients with Cushing's disease: results from a large, 12-month, randomized-dose, double-blind, Phase III study. Abstract# OC1.7.European Neuroendocrine Association (ENEA) 14th Congress
344. **Henry RR, Ciaraldi TP, Armstrong D, et al.** Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013; 98:3446
345. **Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW** 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462
346. **Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A** 2010 Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol 163:709-716
347. **Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW** 2010 Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 362:1846-1848
348. **Curto L, Torre ML, Ferrau F, Pitini V, Altavilla G, Granata F, Longo M, Hofland LJ, Trimarchi F, Cannavo S** 2010 Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. ScientificWorldJournal 10:2132-2138
349. **Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thome C** 2010 SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118:760-763
350. **McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ** 2009 Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71:226-233
351. **Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC** 2008 MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115:261-262
352. **Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA, Jr., Vance ML, Thorner MO, Laws ER, Jr., Lopes MB** 2010 Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95:E280-E290
353. **Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T** 2010 Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95:4592-4599
354. **Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C, Arzt E, Stalla GK** 2001 Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108:1123-1131
355. **Heaney AP, Fernando M, Yong WH, Melmed S** 2002 Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8:1281-1287
356. **Heaney AP, Fernando M, Melmed S** 2003 PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111:1381-1388
357. **Cannavo S, Arosio M, Almoto B, Dall'Asta C, Ambrosi B** 2005 Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease. Clin Endocrinol (Oxf) 63:118-119
358. **Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P** 2004 Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 151:173-178
359. **Suri D, Weiss RE** 2005 Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 90:1340-1346
360. **Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J** 2007 Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J Clin Endocrinol Metab 92:1758-1763
361. **Lacroix A, N'Diaye N, Mircescu H, Tremblay J, Hamet P** 2000 The diversity of abnormal hormone receptors in adrenal Cushing's syndrome allows novel pharmacological therapies. Braz J Med Biol Res 33: 1201-1209
362. **Preumont V, Mermejo LM, Damoiseaux P, Lacroix A, Maiter D** 2011 Transient Efficacy of Octreotide and Pasireotide (SOM230) Treatment in GIP-dependent Cushing's Syndrome. Horm Metab Res
363. **Baulieu EE** 1991 The steroid hormone antagonist RU486. Mechanism at the cellular level and clinical applications. Endocrinol Metab Clin North Am 20:873-891
364. **Bertagna X, Basin C, Picard F, et al.** Peripheral antiglucocorticoid action of RU 486 in man. Clin Endocrinol (Oxf) 1988; 28:537.
365. **Healy DL, Chrousos GP, Schulte HM, Gold PW, Hodgen GD** 1985 Increased adrenocorticotropin, cortisol, and arginine vasopressin secretion in primates after the antiglucocorticoid steroid RU 486: dose response relationships. J Clin Endocrinol Metab 60:1-4
366. **Bertagna X, Bertagna C, Laudat MH, et al.** Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 1986; 63:639.
367. **Fleseriu M, Biller BM, Findling JW, et al.** Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:2039
368. **Castinetti F, Fassnacht M, Johanssen S, et al.** Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009; 160:1003.
369. **Johanssen S, Allolio B.** Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007; 157:561.
370. **Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL** 1985 Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536-540
371. **Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F, Luton JP** 1986 Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 63:639-643
372. **Trainer PJ, Eastment C, Grossman AB, Wheeler MJ, Perry L, Besser GM** 1993 The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome. Clin Endocrinol (Oxf) 39:441-443
373. **Van Seters AP, Moolenaar AJ**. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh) 1991; 124:526.
374. **Alexandraki KI, Kaltsas GA, Le Roux CW, Fassnacht M, Ajodha S, Christ-Crain M, Akker SA, Drake WM, Edwards R, Allolio B, Grossman AB.** Asseesment of serum free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin Endocrinol. (Oxf). 2010 Mar;72(3):305-11
375. **Workman RJ, Vaughn WK, Stone WJ** 1986 Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 63:741-746
376. **Nolan GE, Smith JB, Chavre VJ, Jubiz W** 1981 Spurious overestimation of plasma cortisol in patients with chronic renal failure. J Clin Endocrinol Metab 52:1242-1245
377. **Luger A, Lang I, Kovarik J, Stummvoll HK, Templ H** 1987 Abnormalities in the hypothalamic-pituitary-adrenocortical axis in patients with chronic renal failure. Am J Kidney Dis 9:51-54
378. **Chan KC, Lit LC, Law EL, Tai MH, Yung CU, Chan MH, Lam CW** 2004 Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin Chem 50:757-759
379. **Siamopoulos KC, Dardamanis M, Kyriaki D, Pappas M, Sferopoulos G, Alevisou V** 1990 Pituitary adrenal responsiveness to corticotropin-releasing hormone in chronic uremic patients. Perit Dial Int 10:153-156
380. **Ramirez G, Gomez-Sanchez C, Meikle WA, Jubiz W** 1982 Evaluation of the hypothalamic hypophyseal adrenal axis in patients receiving long-term hemodialysis. Arch Intern Med 142:1448-1452
381. **Lee PD, Winter RJ, Green OC** 1985 Virilizing adrenocortical tumors in childhood: eight cases and a review of the literature. Pediatrics 76:437-444
382. **Savage MO, Lienhardt A, Lebrethon MC, Johnston LB, Huebner A, Grossman AB, Afshar F, Plowman PN, Besser GM** 2001 Cushing's disease in childhood: presentation, investigation, treatment and long-term outcome. Horm Res 55 Suppl 1:24-30
383. **Urbanic RC, George JM** 1981 Cushing's disease--18 years' experience. Medicine (Baltimore) 60:14-24
384. **Streeten DH, Faas FH, Elders MJ, Dalakos TG, Voorhess M** 1975 Hypercortisolism in childhood: shortcomings of conventional diagnostic criteria. Pediatrics 56:797-803
385. **Storr HL, Chan LF, Grossman AB, Savage MO** 2007 Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends Endocrinol Metab 18:167-174
386. **Gafni RI, Papanicolaou DA, Nieman LK** 2000 Nighttime salivary cortisol measurement as a simple, noninvasive, outpatient screening test for Cushing's syndrome in children and adolescents. J Pediatr 137:30-35
387. **Batista DL, Riar J, Keil M, Stratakis CA** 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120:e575-e586
388. **Carpenter PC** 1988 Diagnostic evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am 17:445-472
389. **Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, Cutler GB, Jr., Nieman LK, Chrousos GP** 1994 Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 331:629-636
390. **Dias R, Storr HL, Perry LA, Isidori AM, Grossman AB, Savage MO** 2006 The discriminatory value of the low-dose dexamethasone suppression test in the investigation of paediatric Cushing's syndrome. Horm Res 65:159-162
391. **Hanson JA, Weber A, Reznek RH, Cotterill AM, Ross RJ, Harris RJ, Armstrong P, Savage MO** 1996 Magnetic resonance imaging of adrenocortical adenomas in childhood: correlation with computed tomography and ultrasound. Pediatr Radiol 26:794-799
392. **Storr HL, Afshar F, Matson M, Sabin I, Davies KM, Evanson J, Plowman PN, Besser GM, Monson JP, Grossman AB, Savage MO** 2005 Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. Eur J Endocrinol 152:825-833
393. **Storr HL, Plowman PN, Carroll PV, Francois I, Krassas GE, Afshar F, Besser GM, Grossman AB, Savage MO** 2003 Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease: an effective second-line treatment. J Clin Endocrinol Metab 88:34-37
394. **Davies JH, Storr HL, Davies K, Monson JP, Besser GM, Afshar F, Plowman PN, Grossman AB, Savage MO** 2005 Final adult height and body mass index after cure of paediatric Cushing's disease. Clin Endocrinol (Oxf) 62:466-472
395. **Scommegna S, Greening JP, Storr HL, Davies KM, Shaw NJ, Monson JP, Grossman AB, Savage MO** 2005 Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease. J Endocrinol Invest 28:231-235
396. **Buescher, MA. Cushing's syndrome in pregnancy.** Endocrinologist 1996; 6:357.
397. **Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK**. Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 2005; 90:3077.
398. **Carr BR, Parker CR Jr, Madden JD, et al.** Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy. Am J Obstet Gynecol 1981; 139:416.
399. **Odagiri E, Ishiwatari N, Abe Y, et al**. Hypercortisolism and the resistance to dexamethasone suppression during gestation. Endocrinol Jpn 1988; 35:685.
400. **Barasch E, Sztern M, Spinrad S, et al.** Pregnancy and Cushing's syndrome: example of endocrine interaction. Isr J Med Sci 1988; 24:101.
401. **Abrahamson MJ, Miller JL, Alperstein AL, Barron JL**. Cushing's syndrome in pregnancy. A case report. S Afr Med J 1986; 69:834.
402. **Da Motta LA, Motta LD, Barbosa AM, et al.** Two pregnancies in a Cushing's syndrome. Case report. Panminerva Med 1991; 33:44.
403. **Casson IF, Davis JC, Jeffreys RV, et al.** Successful management of Cushing's disease during pregnancy by transsphenoidal adenectomy. Clin Endocrinol (Oxf) 1987; 27:423.
404. **Ross RJ, Chew SL, Perry L, et al**. Diagnosis and selective cure of Cushing's disease during pregnancy by transsphenoidal surgery. Eur J Endocrinol 1995; 132:722.
405. **Guilhaume B, Sanson ML, BIlaud L et al**. Cushing’s syndrome and pregnancy: aethiologies and prognosis in twenty-two patients, Eur J Med 1992; 1:83
406. **PLOTZ CM, KNOWLTON AI, RAGAN C**. The natural history of Cushing's syndrome. Am J Med 1952; 13:597.
407. **Van Zaane B, Nur E, Squizzato A et al.** Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab 2009; 94:2743
408. **Ntali G, Asimakopoulou A, Siamatras T, Komnionos J, Vassiliadi D, Tzanela M, Tsagarakis S, Grossman AB, Wass JA, Karavitaki N.** Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow up. Eur J Endocrinol 2013 ; 169(5):715-23
409. **Alexandraki K, Kaltsas GA, Isidori AM, Storr HL, Afshar F, Sabin I, Akker SA, Chew SL, Drake WM, Monson JP, Besser GM, Grossman AB.** Long term remission and recurrence rates in Cushing’s disease: predictive factors in a single centre study. Eur J Endocrinol 2013 20;168(4):639-48
410. **Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A, Wilson CB** 2004 Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 89:6348-6357
411. **Swearingen B, Biller BM, Barker FG, Katznelson L, Grinspoon S, Klibanski A, Zervas NT** 1999 Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 130:821-824
412. **Pecori GF, Moro M, Cavagnini F** 2003 Gender-related differences in the presentation and course of Cushing's disease. J Clin Endocrinol Metab 88:1554-1558
413. **Savage MO, Storr HL, Chan LF, Grossman AB** 2007 Diagnosis and treatment of pediatric Cushing's disease. Pituitary
414. **Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK** 2006 Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 91:447-453
415. **Dorn LD, Burgess ES, Friedman TC, et al.** The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997; 82:912.
416. **Bourdeau I, Bard C, Noël B, et al.** Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 2002; 87:1949.
417. **Forget H, Lacroix A, Cohen H.** Persistent cognitive impairment following surgical treatment of Cushing's syndrome.
418. **Manning PJ, Evans MC, Reid IR** 1992 Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf) 36:229-234
419. **Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M, Lombardi G, Colao A** 2003 Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf) 58:302-308
420. **Di Somma C, Colao A, Pivonello R, Klain M, Faggiano A, Tripodi FS, Merola B, Salvatore M, Lombardi G** 1998 Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf) 48:655-662
421. **Lufkin EG, Wahner HW, Bergstralh EJ.** Reversibility of steroid-induced osteoporosis. Am J Med 1988; 85:887.
422. **Hermus AR, Smals AG, Swinkels LM, et al.** Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995; 80:2859.
423. **Di Somma C, Pivonello R, Loche S, et al**. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf) 2003; 58:302.
424. **Wick MR, Rosai J** 1988 Neuroendocrine neoplasms of the thymus. Pathol Res Pract 183:188-199